Open sidebar
Reports

This is a report produced using the OpenSAFELY Platform by: London School of Hygiene & Tropical Medicine

Coverage snapshot - 01 September 2023

Description
Snapshot of COVID-19 vaccination coverage in England as of 01 September 2023. The report is based on individuals 18 years of age or older and registered with practices that use TPP SystmOne software. Summary metrics include dose count, proportion vaccinated in the past 12 or 24 months, and median time since last dose. We report these metrics in demographic and clinical subgroups.
Authors
Edward P K Parker, William J Hulme, Rosalind M Eggo, Linda Nab, Louis Fisher, Emily Herrett, Viyaasan Mahalingasivam, Bang Zheng, Ben Goldacre, Amir Mehrkar, Brian MacKenna, Laurie A Tomlinson
Contact
Get in touch and tell us how you use this report or new features you'd like to see: edward.parker@lshtm.ac.uk
First published
03 Oct 2023
Last released
29 Sep 2023
Links
London School of Hygiene & Tropical Medicine logo

This is a report produced using the OpenSAFELY Platform by: London School of Hygiene & Tropical Medicine

This is a report produced using the OpenSAFELY Platform by the London School of Hygiene & Tropical Medicine in collaboration with the Bennett Institute for Applied Data Science.


OpenSAFELY is a secure analytics platform for electronic patient records built on behalf of NHS England to deliver urgent academic and operational research during the pandemic.

This snapshot of vaccine coverage is an extension of our previous weekly reports on COVID-19 vaccination uptake in England. The snapshot includes data from the 40% of general practices that use TPP electronic health record software. The data requires careful interpretation and there are a number of caveats. Please read the full detail about our methods and discussion of our earlier results in our peer-reviewed publication in the British Journal of General Practice.

The full analytic methods behind the latest results in this report are available here.


Overview of coverage snapshot - 01 September 2023

  • This report summarises the vaccination history of adults in England as of 01 September 2023 - immediately prior to the Autumn 2023 COVID-19 vaccine booster campaign. A summary of COVID-19 vaccine implementation for adults in the UK is given below.

  • Age is calculated at 01 September 2023. Age groups (18-49, 50-64, 65-74, and 75+) reflect the eligibility cut-offs used over successive booster campaigns in the UK, as described below.

  • Clinical subgroups are defined using codelists described in our peer-reviewed publication in the Lancet Public Health.

  • Index of multiple deprivation is a measure of relative deprivation based on the local area in which a patient lives.

  • We do not distinguish between vaccine products or manufacturers (Oxford/AstraZeneca, Pfizer/BioNTech, or Moderna).

  • For calculation of median time since last dose, unvaccinated individuals were assigned a value of 36 months (exceeding the maximum possible value among vaccinated individuals).

  • Patient counts are rounded to the nearest 7. Rounded counts of <=7 are redacted.


Summary charts

Vaccination history by age

Show/hide more details See summary tables for additional data.

In the column on the right, time since last dose is displayed using density plots, which show the relative concentration of values over a given range. In this instance, the height of the lines represents the proportion of individuals, and peaks reflect the timing of different booster campaigns.

Specifically, peaks at 2-6 months reflect individuals most recently vaccinated during the Spring 2023 booster campaign, peaks at 9-12 months reflect individuals most recently vaccinated during the Autumn 2022 campaign, and peaks at 18-24 months reflect individuals most recently vaccinated during the Autumn 2021 booster campaign. Further details on the timing and eligibility for each campaign can be found below.

In addition to these density plots, the average (median) time since last dose for each subgroup is provided in the summary tables.

Abbreviation: Unvax = unvaccinated.


Vaccination history by age and ethnicity

Show/hide more details See summary tables for additional data, including vaccination history according to more narrowly defined ethnic groups.

In the column on the right, time since last dose is displayed using density plots, which show the relative concentration of values over a given range. In this instance, the height of the lines represents the proportion of individuals, and peaks reflect the timing of different booster campaigns.

Specifically, peaks at 2-6 months reflect individuals most recently vaccinated during the Spring 2023 booster campaign, peaks at 9-12 months reflect individuals most recently vaccinated during the Autumn 2022 campaign, and peaks at 18-24 months reflect individuals most recently vaccinated during the Autumn 2021 booster campaign. Further details on the timing and eligibility for each campaign can be found below.

In addition to these density plots, the average (median) time since last dose for each subgroup is provided in the summary tables.

Abbreviation: Unvax = unvaccinated.


Vaccination history by age and index of multiple deprivation

Show/hide more details See summary tables for additional data.

In the column on the right, time since last dose is displayed using density plots, which show the relative concentration of values over a given range. In this instance, the height of the lines represents the proportion of individuals, and peaks reflect the timing of different booster campaigns.

Specifically, peaks at 2-6 months reflect individuals most recently vaccinated during the Spring 2023 booster campaign, peaks at 9-12 months reflect individuals most recently vaccinated during the Autumn 2022 campaign, and peaks at 18-24 months reflect individuals most recently vaccinated during the Autumn 2021 booster campaign. Further details on the timing and eligibility for each campaign can be found below.

In addition to these density plots, the average (median) time since last dose for each subgroup is provided in the summary tables.

Abbreviation: Unvax = unvaccinated.


Summary tables

Vaccination history by age

Age group N Dose count Dose count, median (IQR) Vaccinated in past 12 months, n (%) Vaccinated in past 24 months, n (%) Time in months since last dose, median (IQR)
0 1 2 3 4 5+
75+ 2,347,184 69,090 (2.9%) 16,625 (0.7%) 43,253 (1.8%) 125,720 (5.4%) 214,837 (9.2%) 1,877,659 (80%) 6 (5-6) 2,063,810 (87.9%) 2,241,561 (95.5%) 4.1 (3.5-9.7)
65-74 2,409,799 134,617 (5.6%) 26,901 (1.1%) 87,500 (3.6%) 310,415 (12.9%) 1,666,245 (69.1%) 184,121 (7.6%) 4 (4-4) 1,881,838 (78.1%) 2,198,903 (91.2%) 10.8 (10.4-11.5)
50-64 4,861,332 501,767 (10.3%) 82,369 (1.7%) 405,447 (8.3%) 1,337,644 (27.5%) 2,383,045 (49%) 151,060 (3.1%) 4 (3-4) 2,594,739 (53.4%) 4,001,774 (82.3%) 11 (10.1-21.2)
18-49 10,093,706 2,821,343 (28%) 477,582 (4.7%) 2,063,439 (20.4%) 3,987,690 (39.5%) 686,329 (6.8%) 57,323 (0.6%) 2 (0-3) 859,817 (8.5%) 6,105,316 (60.5%) 20.9 (20-36)
Abbreviation: IQR = interquartile range.


75y+ population: Vaccination history by demographic and clinical subgroups

Show/hide table

Level N Dose count Dose count, median (IQR) Vaccinated in past 12 months, n (%) Vaccinated in past 24 months, n (%) Time in months since last dose, median (IQR)
0 1 2 3 4 5+
Sex
Female 1,311,702 38,941 (3%) 10,031 (0.8%) 26,677 (2%) 75,852 (5.8%) 123,767 (9.4%) 1,036,434 (79%) 6 (5-6) 1,142,554 (87.1%) 1,249,857 (95.3%) 4.1 (3.7-10.1)
Male 1,035,482 30,149 (2.9%) 6,594 (0.6%) 16,569 (1.6%) 49,868 (4.8%) 91,070 (8.8%) 841,225 (81.2%) 6 (5-6) 921,256 (89%) 991,704 (95.8%) 4.1 (3.5-9.2)
Ethnicity (broad categories)
White 2,188,739 46,235 (2.1%) 13,839 (0.6%) 33,348 (1.5%) 104,279 (4.8%) 193,676 (8.8%) 1,797,355 (82.1%) 6 (5-6) 1,966,293 (89.8%) 2,114,623 (96.6%) 4.1 (3.5-8.5)
Mixed 7,203 945 (13.1%) 140 (1.9%) 378 (5.2%) 826 (11.5%) 903 (12.5%) 4,018 (55.8%) 5 (3-6) 4,809 (66.8%) 5,929 (82.3%) 9.2 (3.7-20.7)
South Asian 57,253 5,411 (9.5%) 1,274 (2.2%) 5,208 (9.1%) 11,025 (19.3%) 9,562 (16.7%) 24,766 (43.3%) 4 (3-5) 32,298 (56.4%) 47,418 (82.8%) 11 (4.1-21.6)
Black 19,124 3,892 (20.4%) 511 (2.7%) 1,750 (9.2%) 3,199 (16.7%) 2,744 (14.3%) 7,042 (36.8%) 4 (2-5) 9,289 (48.6%) 13,699 (71.6%) 13.8 (4.4-27.6)
Other 15,967 2,359 (14.8%) 322 (2%) 819 (5.1%) 1,855 (11.6%) 2,086 (13.1%) 8,526 (53.4%) 5 (3-6) 10,367 (64.9%) 12,943 (81.1%) 9.9 (3.9-21.2)
Unknown 58,891 10,248 (17.4%) 546 (0.9%) 1,750 (3%) 4,543 (7.7%) 5,866 (10%) 35,945 (61%) 5 (3-6) 40,761 (69.2%) 46,949 (79.7%) 4.4 (3.7-20.9)
Ethnicity (narrow categories)
British or Mixed British 2,073,505 38,136 (1.8%) 12,586 (0.6%) 30,191 (1.5%) 96,005 (4.6%) 181,720 (8.8%) 1,714,867 (82.7%) 6 (5-6) 1,873,557 (90.4%) 2,010,183 (96.9%) 4.1 (3.5-4.8)
Irish 19,544 749 (3.8%) 217 (1.1%) 490 (2.5%) 1,533 (7.8%) 2,296 (11.7%) 14,259 (73%) 6 (4-6) 16,268 (83.2%) 18,403 (94.2%) 4.4 (3.7-10.8)
Other White 95,669 7,343 (7.7%) 1,043 (1.1%) 2,667 (2.8%) 6,741 (7%) 9,660 (10.1%) 68,215 (71.3%) 6 (4-6) 76,440 (79.9%) 86,016 (89.9%) 4.4 (3.7-11)
White + Black Caribbean 2,002 322 (16.1%) 42 (2.1%) 126 (6.3%) 294 (14.7%) 280 (14%) 945 (47.2%) 4 (3-6) 1,176 (58.7%) 1,568 (78.3%) 10.6 (3.9-22.1)
White + Black African 987 203 (20.6%) 28 (2.8%) 63 (6.4%) 126 (12.8%) 126 (12.8%) 441 (44.7%) 4 (2-6) 567 (57.4%) 728 (73.8%) 10.8 (3.9-27.4)
White + Asian 1,365 119 (8.7%) 21 (1.5%) 49 (3.6%) 119 (8.7%) 182 (13.3%) 875 (64.1%) 5 (4-6) 1,022 (74.9%) 1,204 (88.2%) 4.4 (3.7-12.3)
Other mixed 2,849 294 (10.3%) 42 (1.5%) 140 (4.9%) 287 (10.1%) 322 (11.3%) 1,764 (61.9%) 5 (3-6) 2,051 (72%) 2,436 (85.5%) 4.4 (3.7-16.3)
Indian or British Indian 30,912 2,135 (6.9%) 539 (1.7%) 1,407 (4.6%) 4,564 (14.8%) 5,565 (18%) 16,695 (54%) 5 (3-6) 20,944 (67.8%) 27,650 (89.4%) 10.4 (3.9-18.2)
Pakistani or British Pakistani 13,132 1,708 (13%) 406 (3.1%) 2,751 (20.9%) 4,011 (30.5%) 1,806 (13.8%) 2,450 (18.7%) 3 (2-4) 3,871 (29.5%) 8,974 (68.3%) 20.9 (10.8-27.4)
Bangladeshi or British Bangladeshi 2,247 273 (12.1%) 77 (3.4%) 336 (15%) 623 (27.7%) 392 (17.4%) 546 (24.3%) 3 (2-4) 910 (40.5%) 1,673 (74.5%) 19.8 (9.9-24.9)
Other Asian 10,962 1,302 (11.9%) 245 (2.2%) 714 (6.5%) 1,834 (16.7%) 1,799 (16.4%) 5,068 (46.2%) 4 (3-6) 6,566 (59.9%) 9,114 (83.1%) 10.6 (3.9-21.4)
Caribbean 10,738 1,960 (18.3%) 224 (2.1%) 896 (8.3%) 1,876 (17.5%) 1,568 (14.6%) 4,207 (39.2%) 4 (2-5) 5,404 (50.3%) 7,931 (73.9%) 11.7 (4.1-26.7)
African 4,921 1,260 (25.6%) 189 (3.8%) 567 (11.5%) 812 (16.5%) 679 (13.8%) 1,414 (28.7%) 3 (0-5) 2,051 (41.7%) 3,206 (65.1%) 19.8 (8.5-36)
Other Black 3,472 665 (19.2%) 98 (2.8%) 280 (8.1%) 504 (14.5%) 490 (14.1%) 1,421 (40.9%) 4 (2-6) 1,841 (53%) 2,562 (73.8%) 11.3 (4.1-26.5)
Chinese 4,242 756 (17.8%) 77 (1.8%) 140 (3.3%) 350 (8.3%) 532 (12.5%) 2,387 (56.3%) 5 (3-6) 2,884 (68%) 3,388 (79.9%) 9.2 (3.7-20.5)
Other 11,725 1,603 (13.7%) 238 (2%) 679 (5.8%) 1,505 (12.8%) 1,561 (13.3%) 6,132 (52.3%) 5 (3-6) 7,476 (63.8%) 9,555 (81.5%) 10.1 (3.9-21.4)
Unknown 58,912 10,248 (17.4%) 539 (0.9%) 1,750 (3%) 4,543 (7.7%) 5,859 (9.9%) 35,966 (61.1%) 5 (3-6) 40,775 (69.2%) 46,963 (79.7%) 4.4 (3.7-20.9)
IMD quintile
5 (least deprived) 559,412 10,675 (1.9%) 3,206 (0.6%) 6,468 (1.2%) 20,293 (3.6%) 41,454 (7.4%) 477,309 (85.3%) 6 (5-6) 514,801 (92%) 543,795 (97.2%) 4.1 (3.5-4.4)
4 570,458 13,790 (2.4%) 3,808 (0.7%) 8,197 (1.4%) 24,612 (4.3%) 47,026 (8.2%) 473,032 (82.9%) 6 (5-6) 514,640 (90.2%) 550,060 (96.4%) 4.1 (3.5-4.8)
3 531,013 14,784 (2.8%) 3,675 (0.7%) 8,911 (1.7%) 27,433 (5.2%) 48,202 (9.1%) 428,015 (80.6%) 6 (5-6) 469,931 (88.5%) 508,795 (95.8%) 4.1 (3.5-9.7)
2 392,861 14,700 (3.7%) 3,101 (0.8%) 8,925 (2.3%) 26,173 (6.7%) 41,321 (10.5%) 298,634 (76%) 6 (5-6) 333,431 (84.9%) 370,328 (94.3%) 4.1 (3.5-10.6)
1 (most deprived) 293,440 15,148 (5.2%) 2,842 (1%) 10,738 (3.7%) 27,209 (9.3%) 36,834 (12.6%) 200,669 (68.4%) 5 (4-6) 231,007 (78.7%) 268,583 (91.5%) 4.4 (3.7-11.3)
Body Mass Index
Not obese 1,865,633 60,438 (3.2%) 13,755 (0.7%) 34,804 (1.9%) 99,239 (5.3%) 165,620 (8.9%) 1,491,784 (80%) 6 (5-6) 1,635,781 (87.7%) 1,775,872 (95.2%) 4.1 (3.7-9.7)
Obese I (30-34.9 kg/m2) 337,274 5,789 (1.7%) 2,009 (0.6%) 5,705 (1.7%) 17,815 (5.3%) 32,830 (9.7%) 273,133 (81%) 6 (5-6) 301,301 (89.3%) 326,704 (96.9%) 4.1 (3.5-9.4)
Obese II (35-39.9 kg/m2) 104,552 1,988 (1.9%) 609 (0.6%) 1,918 (1.8%) 6,090 (5.8%) 11,291 (10.8%) 82,656 (79.1%) 6 (5-6) 92,218 (88.2%) 100,877 (96.5%) 4.1 (3.5-10.1)
Obese III (40+ kg/m2) 39,732 875 (2.2%) 259 (0.7%) 826 (2.1%) 2,583 (6.5%) 5,096 (12.8%) 30,086 (75.7%) 6 (5-6) 34,517 (86.9%) 38,108 (95.9%) 4.1 (3.5-10.4)
Smoking status
Never and unknown 948,066 37,205 (3.9%) 7,581 (0.8%) 19,313 (2%) 51,800 (5.5%) 84,336 (8.9%) 747,838 (78.9%) 6 (5-6) 821,961 (86.7%) 894,852 (94.4%) 4.1 (3.7-9.9)
Former 1,276,226 25,802 (2%) 7,945 (0.6%) 19,565 (1.5%) 60,795 (4.8%) 112,049 (8.8%) 1,050,077 (82.3%) 6 (5-6) 1,147,097 (89.9%) 1,234,149 (96.7%) 4.1 (3.5-8.5)
Current 122,892 6,083 (4.9%) 1,106 (0.9%) 4,368 (3.6%) 13,132 (10.7%) 18,459 (15%) 79,744 (64.9%) 5 (4-6) 94,745 (77.1%) 112,560 (91.6%) 4.4 (3.7-11.3)
Asthma
No asthma 2,039,135 62,699 (3.1%) 14,511 (0.7%) 37,604 (1.8%) 109,144 (5.4%) 186,361 (9.1%) 1,628,809 (79.9%) 6 (5-6) 1,790,642 (87.8%) 1,944,754 (95.4%) 4.1 (3.5-9.9)
With no oral steroid use 255,206 5,691 (2.2%) 1,806 (0.7%) 4,641 (1.8%) 13,601 (5.3%) 23,401 (9.2%) 206,066 (80.7%) 6 (5-6) 226,170 (88.6%) 245,539 (96.2%) 4.1 (3.5-9.4)
With oral steroid use 52,843 693 (1.3%) 315 (0.6%) 1,001 (1.9%) 2,975 (5.6%) 5,082 (9.6%) 42,777 (81%) 6 (5-6) 46,998 (88.9%) 51,268 (97%) 4.1 (3.5-9.7)
Diabetes
No diabetes 1,637,384 53,403 (3.3%) 11,466 (0.7%) 28,280 (1.7%) 83,475 (5.1%) 146,706 (9%) 1,314,054 (80.3%) 6 (5-6) 1,442,287 (88.1%) 1,559,964 (95.3%) 4.1 (3.5-9.7)
Controlled 649,103 11,683 (1.8%) 4,354 (0.7%) 12,845 (2%) 37,121 (5.7%) 61,453 (9.5%) 521,640 (80.4%) 6 (5-6) 573,902 (88.4%) 626,808 (96.6%) 4.1 (3.5-9.7)
Not controlled 15,029 273 (1.8%) 112 (0.7%) 301 (2%) 980 (6.5%) 1,554 (10.3%) 11,816 (78.6%) 6 (5-6) 13,160 (87.6%) 14,525 (96.6%) 4.1 (3.5-10.1)
Without recent Hb1ac measure 45,668 3,731 (8.2%) 693 (1.5%) 1,827 (4%) 4,144 (9.1%) 5,131 (11.2%) 30,149 (66%) 5 (4-6) 34,468 (75.5%) 40,271 (88.2%) 4.4 (3.7-11.5)
CKD or RRT
No CKD or RRT 1,609,447 56,259 (3.5%) 11,613 (0.7%) 30,324 (1.9%) 87,731 (5.5%) 153,475 (9.5%) 1,270,045 (78.9%) 6 (5-6) 1,405,152 (87.3%) 1,527,246 (94.9%) 4.1 (3.5-9.9)
CKD stage 3a 468,853 8,001 (1.7%) 3,038 (0.6%) 7,826 (1.7%) 23,646 (5%) 38,696 (8.3%) 387,646 (82.7%) 6 (5-6) 420,196 (89.6%) 454,489 (96.9%) 4.1 (3.5-8.7)
CKD stage 3b 209,965 3,647 (1.7%) 1,526 (0.7%) 3,857 (1.8%) 10,969 (5.2%) 17,332 (8.3%) 172,641 (82.2%) 6 (5-6) 186,823 (89%) 203,119 (96.7%) 4.1 (3.5-9.2)
CKD stage 4 49,819 994 (2%) 399 (0.8%) 1,036 (2.1%) 2,758 (5.5%) 4,424 (8.9%) 40,208 (80.7%) 6 (5-6) 43,841 (88%) 47,971 (96.3%) 4.1 (3.5-9.9)
CKD stage 5 4,025 84 (2.1%) 35 (0.9%) 112 (2.8%) 301 (7.5%) 420 (10.4%) 3,080 (76.5%) 6 (5-6) 3,409 (84.7%) 3,857 (95.8%) 4.1 (3.5-10.4)
RRT (dialysis) 3,969 84 (2.1%) 21 (0.5%) 77 (1.9%) 273 (6.9%) 420 (10.6%) 3,087 (77.8%) 6 (5-6) 3,395 (85.5%) 3,815 (96.1%) 4.1 (3.5-10.4)
RRT (transplant) 1,099 21 (1.9%) [Redacted] 21 (1.9%) 42 (3.8%) 70 (6.4%) 945 (86%) 6 (5-7) 994 (90.4%) 1,064 (96.8%) 4.1 (3.5-4.6)
Organ transplant
No transplant 2,345,245 69,055 (2.9%) 16,618 (0.7%) 43,225 (1.8%) 125,636 (5.4%) 214,718 (9.2%) 1,875,993 (80%) 6 (5-6) 2,062,060 (87.9%) 2,239,678 (95.5%) 4.1 (3.5-9.7)
Kidney transplant 1,344 21 (1.6%) [Redacted] 21 (1.6%) 49 (3.6%) 84 (6.2%) 1,162 (86.5%) 6 (5-7) 1,218 (90.6%) 1,302 (96.9%) 4.1 (3.5-4.6)
Other organ transplant 595 [Redacted] [Redacted] [Redacted] 35 (5.9%) 42 (7.1%) 504 (84.7%) 6 (5-6) 532 (89.4%) 581 (97.6%) 4.1 (3.5-4.7)
Hypertension
No 585,410 26,201 (4.5%) 4,921 (0.8%) 11,438 (2%) 31,563 (5.4%) 55,706 (9.5%) 455,574 (77.8%) 6 (5-6) 506,058 (86.4%) 549,773 (93.9%) 4.1 (3.7-10.1)
Yes 1,761,774 42,889 (2.4%) 11,704 (0.7%) 31,808 (1.8%) 94,164 (5.3%) 159,131 (9%) 1,422,085 (80.7%) 6 (5-6) 1,557,759 (88.4%) 1,691,788 (96%) 4.1 (3.5-9.7)
Chronic respiratory disease
No 2,045,463 63,602 (3.1%) 14,609 (0.7%) 37,562 (1.8%) 108,472 (5.3%) 185,724 (9.1%) 1,635,494 (80%) 6 (5-6) 1,797,362 (87.9%) 1,950,319 (95.3%) 4.1 (3.7-9.7)
Yes 301,721 5,481 (1.8%) 2,016 (0.7%) 5,691 (1.9%) 17,248 (5.7%) 29,120 (9.7%) 242,165 (80.3%) 6 (5-6) 266,448 (88.3%) 291,242 (96.5%) 4.1 (3.5-9.9)
Chronic cardiac disease
No 1,749,734 57,778 (3.3%) 12,593 (0.7%) 32,340 (1.8%) 94,213 (5.4%) 162,673 (9.3%) 1,390,137 (79.4%) 6 (5-6) 1,532,629 (87.6%) 1,664,747 (95.1%) 4.1 (3.7-9.9)
Yes 597,450 11,312 (1.9%) 4,032 (0.7%) 10,906 (1.8%) 31,507 (5.3%) 52,164 (8.7%) 487,522 (81.6%) 6 (5-6) 531,181 (88.9%) 576,814 (96.5%) 4.1 (3.5-9.4)
Cancer (non-haematological)
No 1,922,403 62,363 (3.2%) 14,182 (0.7%) 37,345 (1.9%) 107,051 (5.6%) 180,873 (9.4%) 1,520,589 (79.1%) 6 (5-6) 1,678,103 (87.3%) 1,828,337 (95.1%) 4.1 (3.5-9.9)
Yes 424,781 6,727 (1.6%) 2,443 (0.6%) 5,901 (1.4%) 18,669 (4.4%) 33,971 (8%) 357,063 (84.1%) 6 (5-6) 385,707 (90.8%) 413,224 (97.3%) 4.1 (3.5-4.6)
Haematological malignancy
No 2,304,491 68,446 (3%) 16,366 (0.7%) 42,672 (1.9%) 124,040 (5.4%) 212,121 (9.2%) 1,840,839 (79.9%) 6 (5-6) 2,024,988 (87.9%) 2,200,002 (95.5%) 4.1 (3.5-9.9)
Yes 42,693 637 (1.5%) 259 (0.6%) 574 (1.3%) 1,687 (4%) 2,716 (6.4%) 36,820 (86.2%) 6 (5-6) 38,822 (90.9%) 41,559 (97.3%) 4.1 (3.7-4.6)
Chronic liver disease
No 2,326,289 68,642 (3%) 16,471 (0.7%) 42,833 (1.8%) 124,460 (5.4%) 212,744 (9.1%) 1,861,139 (80%) 6 (5-6) 2,045,526 (87.9%) 2,221,471 (95.5%) 4.1 (3.5-9.7)
Yes 20,895 448 (2.1%) 154 (0.7%) 413 (2%) 1,260 (6%) 2,100 (10.1%) 16,520 (79.1%) 6 (5-6) 18,284 (87.5%) 20,097 (96.2%) 4.1 (3.5-9.9)
Stroke
No 2,124,031 64,400 (3%) 14,693 (0.7%) 38,682 (1.8%) 113,099 (5.3%) 194,712 (9.2%) 1,698,452 (80%) 6 (5-6) 1,867,187 (87.9%) 2,026,941 (95.4%) 4.1 (3.5-9.9)
Yes 223,153 4,690 (2.1%) 1,932 (0.9%) 4,571 (2%) 12,628 (5.7%) 20,132 (9%) 179,200 (80.3%) 6 (5-6) 196,623 (88.1%) 214,620 (96.2%) 4.1 (3.7-9.7)
Dementia
No 2,313,017 68,313 (3%) 16,044 (0.7%) 42,273 (1.8%) 123,697 (5.3%) 211,330 (9.1%) 1,851,360 (80%) 6 (5-6) 2,033,724 (87.9%) 2,208,794 (95.5%) 4.1 (3.5-9.7)
Yes 34,167 777 (2.3%) 581 (1.7%) 980 (2.9%) 2,030 (5.9%) 3,507 (10.3%) 26,299 (77%) 6 (5-6) 30,086 (88.1%) 32,767 (95.9%) 4.4 (3.7-9.7)
Neurological disease
No 2,293,039 68,019 (3%) 16,121 (0.7%) 42,210 (1.8%) 123,018 (5.4%) 209,881 (9.2%) 1,833,797 (80%) 6 (5-6) 2,015,342 (87.9%) 2,189,285 (95.5%) 4.1 (3.5-9.9)
Yes 54,145 1,071 (2%) 511 (0.9%) 1,043 (1.9%) 2,702 (5%) 4,956 (9.2%) 43,862 (81%) 6 (5-6) 48,475 (89.5%) 52,276 (96.5%) 4.1 (3.5-9)
Asplenia
No 2,341,283 68,971 (2.9%) 16,590 (0.7%) 43,155 (1.8%) 125,482 (5.4%) 214,417 (9.2%) 1,872,668 (80%) 6 (5-6) 2,058,441 (87.9%) 2,235,856 (95.5%) 4.1 (3.5-9.7)
Yes 5,901 119 (2%) 35 (0.6%) 91 (1.5%) 245 (4.2%) 427 (7.2%) 4,984 (84.5%) 6 (5-6) 5,369 (91%) 5,705 (96.7%) 4.1 (3.5-4.6)
Rheumatoid arthritis, lupus, or psoriasis
No 2,159,696 65,681 (3%) 15,463 (0.7%) 40,243 (1.9%) 116,186 (5.4%) 198,527 (9.2%) 1,723,589 (79.8%) 6 (5-6) 1,896,146 (87.8%) 2,060,128 (95.4%) 4.1 (3.5-9.9)
Yes 187,488 3,402 (1.8%) 1,162 (0.6%) 3,010 (1.6%) 9,534 (5.1%) 16,310 (8.7%) 154,070 (82.2%) 6 (5-6) 167,664 (89.4%) 181,433 (96.8%) 4.1 (3.5-9.2)
Immunodeficiency
No 2,270,786 67,844 (3%) 16,114 (0.7%) 42,133 (1.9%) 122,430 (5.4%) 209,566 (9.2%) 1,812,699 (79.8%) 6 (5-6) 1,994,860 (87.8%) 2,167,375 (95.4%) 4.1 (3.5-9.9)
Yes 76,398 1,246 (1.6%) 511 (0.7%) 1,120 (1.5%) 3,297 (4.3%) 5,278 (6.9%) 64,960 (85%) 6 (5-6) 68,957 (90.3%) 74,186 (97.1%) 4.1 (3.5-4.6)
Learning disability
No 2,343,768 68,999 (2.9%) 16,590 (0.7%) 43,141 (1.8%) 125,489 (5.4%) 214,221 (9.1%) 1,875,328 (80%) 6 (5-6) 2,060,905 (87.9%) 2,238,327 (95.5%) 4.1 (3.5-9.7)
Yes 3,416 91 (2.7%) 42 (1.2%) 105 (3.1%) 231 (6.8%) 616 (18%) 2,331 (68.2%) 5 (4-6) 2,912 (85.2%) 3,234 (94.7%) 4.4 (3.5-10.6)
Severe mental illness
No 2,322,397 67,760 (2.9%) 16,254 (0.7%) 42,357 (1.8%) 123,802 (5.3%) 211,799 (9.1%) 1,860,432 (80.1%) 6 (5-6) 2,043,699 (88%) 2,218,916 (95.5%) 4.1 (3.5-9.7)
Yes 24,787 1,323 (5.3%) 371 (1.5%) 896 (3.6%) 1,925 (7.8%) 3,045 (12.3%) 17,227 (69.5%) 5 (4-6) 20,111 (81.1%) 22,645 (91.4%) 4.4 (3.7-10.8)


Abbreviations: CKD = chronic kidney disease; IMD = index of multiple deprivation; IQR = interquartile range; RRT = renal replacement therapy.


65-74y population: Vaccination history by demographic and clinical subgroups

Show/hide table

Level N Dose count Dose count, median (IQR) Vaccinated in past 12 months, n (%) Vaccinated in past 24 months, n (%) Time in months since last dose, median (IQR)
0 1 2 3 4 5+
Sex
Female 1,240,022 66,094 (5.3%) 14,084 (1.1%) 46,732 (3.8%) 159,040 (12.8%) 855,365 (69%) 98,707 (8%) 4 (4-4) 969,465 (78.2%) 1,133,076 (91.4%) 10.8 (10.4-11.5)
Male 1,169,777 68,523 (5.9%) 12,817 (1.1%) 40,775 (3.5%) 151,375 (12.9%) 810,880 (69.3%) 85,414 (7.3%) 4 (4-4) 912,373 (78%) 1,065,827 (91.1%) 10.8 (10.4-11.5)
Ethnicity (broad categories)
White 2,150,554 91,385 (4.2%) 21,210 (1%) 64,225 (3%) 254,128 (11.8%) 1,544,102 (71.8%) 175,504 (8.2%) 4 (4-4) 1,746,955 (81.2%) 2,002,602 (93.1%) 10.8 (10.4-11.3)
Mixed 11,921 1,911 (16%) 280 (2.3%) 959 (8%) 2,317 (19.4%) 5,782 (48.5%) 679 (5.7%) 4 (2-4) 6,692 (56.1%) 9,205 (77.2%) 11.3 (10.6-22.1)
South Asian 101,710 10,507 (10.3%) 2,604 (2.6%) 12,243 (12%) 28,553 (28.1%) 43,722 (43%) 4,088 (4%) 3 (3-4) 49,518 (48.7%) 81,130 (79.8%) 17 (10.6-22.1)
Black 29,295 6,860 (23.4%) 861 (2.9%) 3,682 (12.6%) 6,825 (23.3%) 9,996 (34.1%) 1,071 (3.7%) 3 (1-4) 11,704 (40%) 19,362 (66.1%) 20.5 (10.8-28.3)
Other 29,239 5,768 (19.7%) 847 (2.9%) 2,198 (7.5%) 5,397 (18.5%) 13,741 (47%) 1,295 (4.4%) 4 (2-4) 15,841 (54.2%) 21,812 (74.6%) 11.5 (10.6-25.1)
Unknown 87,073 18,186 (20.9%) 1,099 (1.3%) 4,200 (4.8%) 13,195 (15.2%) 48,895 (56.2%) 1,498 (1.7%) 4 (2-4) 51,121 (58.7%) 64,799 (74.4%) 11.3 (10.6-26.2)
Ethnicity (narrow categories)
British or Mixed British 2,013,886 69,188 (3.4%) 18,746 (0.9%) 56,175 (2.8%) 232,995 (11.6%) 1,469,615 (73%) 167,167 (8.3%) 4 (4-4) 1,662,024 (82.5%) 1,895,229 (94.1%) 10.8 (10.4-11.3)
Irish 16,422 1,092 (6.6%) 245 (1.5%) 728 (4.4%) 2,604 (15.9%) 10,458 (63.7%) 1,281 (7.8%) 4 (3-4) 12,089 (73.6%) 14,721 (89.6%) 11 (10.4-19.8)
Other White 120,211 21,112 (17.6%) 2,219 (1.8%) 7,315 (6.1%) 18,515 (15.4%) 64,001 (53.2%) 7,049 (5.9%) 4 (2-4) 72,821 (60.6%) 92,610 (77%) 11.3 (10.6-22.1)
White + Black Caribbean 2,632 504 (19.1%) 70 (2.7%) 287 (10.9%) 581 (22.1%) 1,050 (39.9%) 140 (5.3%) 3 (2-4) 1,239 (47.1%) 1,862 (70.7%) 19.8 (10.6-27.2)
White + Black African 2,086 427 (20.5%) 56 (2.7%) 196 (9.4%) 427 (20.5%) 882 (42.3%) 105 (5%) 3 (2-4) 1,043 (50%) 1,512 (72.5%) 12.3 (10.6-26.9)
White + Asian 2,352 245 (10.4%) 49 (2.1%) 147 (6.2%) 413 (17.6%) 1,351 (57.4%) 154 (6.5%) 4 (3-4) 1,547 (65.8%) 1,995 (84.8%) 11 (10.4-20.9)
Other mixed 4,858 728 (15%) 112 (2.3%) 329 (6.8%) 896 (18.4%) 2,513 (51.7%) 280 (5.8%) 4 (3-4) 2,870 (59.1%) 3,843 (79.1%) 11.3 (10.6-21.9)
Indian or British Indian 52,570 4,445 (8.5%) 1,239 (2.4%) 3,619 (6.9%) 13,209 (25.1%) 27,377 (52.1%) 2,681 (5.1%) 4 (3-4) 30,849 (58.7%) 45,115 (85.8%) 11.3 (10.6-21.4)
Pakistani or British Pakistani 24,983 3,199 (12.8%) 721 (2.9%) 6,272 (25.1%) 8,981 (35.9%) 5,404 (21.6%) 399 (1.6%) 3 (2-3) 6,139 (24.6%) 16,548 (66.2%) 21.2 (13.8-27.2)
Bangladeshi or British Bangladeshi 4,305 441 (10.2%) 140 (3.3%) 707 (16.4%) 1,526 (35.4%) 1,393 (32.4%) 98 (2.3%) 3 (2-4) 1,610 (37.4%) 3,269 (75.9%) 20.5 (10.8-23)
Other Asian 19,838 2,415 (12.2%) 511 (2.6%) 1,638 (8.3%) 4,830 (24.3%) 9,541 (48.1%) 910 (4.6%) 4 (3-4) 10,913 (55%) 16,184 (81.6%) 11.3 (10.6-21.9)
Caribbean 10,997 2,793 (25.4%) 266 (2.4%) 1,449 (13.2%) 2,625 (23.9%) 3,486 (31.7%) 378 (3.4%) 3 (0-4) 4,025 (36.6%) 6,895 (62.7%) 20.9 (10.8-36)
African 11,382 2,660 (23.4%) 392 (3.4%) 1,526 (13.4%) 2,702 (23.7%) 3,731 (32.8%) 378 (3.3%) 3 (1-4) 4,459 (39.2%) 7,553 (66.4%) 20.5 (10.8-28.3)
Other Black 6,923 1,414 (20.4%) 196 (2.8%) 707 (10.2%) 1,505 (21.7%) 2,779 (40.1%) 315 (4.6%) 3 (2-4) 3,227 (46.6%) 4,921 (71.1%) 19.6 (10.6-27.4)
Chinese 9,128 1,862 (20.4%) 287 (3.1%) 455 (5%) 1,176 (12.9%) 4,963 (54.4%) 385 (4.2%) 4 (2-4) 5,705 (62.5%) 7,007 (76.8%) 11.3 (10.4-21.9)
Other 20,125 3,906 (19.4%) 560 (2.8%) 1,743 (8.7%) 4,228 (21%) 8,785 (43.7%) 903 (4.5%) 3 (2-4) 10,136 (50.4%) 14,812 (73.6%) 11.5 (10.6-26.5)
Unknown 87,094 18,186 (20.9%) 1,099 (1.3%) 4,200 (4.8%) 13,209 (15.2%) 48,902 (56.1%) 1,498 (1.7%) 4 (2-4) 51,128 (58.7%) 64,820 (74.4%) 11.3 (10.6-26.2)
IMD quintile
5 (least deprived) 523,355 18,893 (3.6%) 4,893 (0.9%) 11,046 (2.1%) 47,698 (9.1%) 398,825 (76.2%) 42,000 (8%) 4 (4-4) 447,685 (85.5%) 495,586 (94.7%) 10.8 (10.4-11.3)
4 553,245 24,955 (4.5%) 5,642 (1%) 14,700 (2.7%) 60,011 (10.8%) 403,816 (73%) 44,114 (8%) 4 (4-4) 455,427 (82.3%) 516,187 (93.3%) 10.8 (10.4-11.3)
3 537,985 28,777 (5.3%) 5,985 (1.1%) 17,549 (3.3%) 66,871 (12.4%) 377,181 (70.1%) 41,622 (7.7%) 4 (4-4) 426,027 (79.2%) 494,067 (91.8%) 10.8 (10.4-11.5)
2 433,580 29,841 (6.9%) 5,348 (1.2%) 19,551 (4.5%) 66,605 (15.4%) 280,546 (64.7%) 31,696 (7.3%) 4 (3-4) 317,954 (73.3%) 386,400 (89.1%) 11 (10.4-19.8)
1 (most deprived) 361,627 32,151 (8.9%) 5,026 (1.4%) 24,654 (6.8%) 69,237 (19.1%) 205,877 (56.9%) 24,682 (6.8%) 4 (3-4) 234,752 (64.9%) 306,663 (84.8%) 11 (10.4-20.9)
Body Mass Index
Not obese 1,761,102 111,888 (6.4%) 20,447 (1.2%) 65,058 (3.7%) 227,290 (12.9%) 1,208,865 (68.6%) 127,554 (7.2%) 4 (4-4) 1,359,617 (77.2%) 1,592,192 (90.4%) 10.8 (10.4-11.5)
Obese I (30-34.9 kg/m2) 406,679 14,189 (3.5%) 4,074 (1%) 13,720 (3.4%) 51,338 (12.6%) 288,715 (71%) 34,643 (8.5%) 4 (4-4) 328,636 (80.8%) 380,884 (93.7%) 10.8 (10.4-11.3)
Obese II (35-39.9 kg/m2) 158,662 5,537 (3.5%) 1,512 (1%) 5,579 (3.5%) 20,349 (12.8%) 111,482 (70.3%) 14,196 (8.9%) 4 (4-4) 127,624 (80.4%) 148,295 (93.5%) 10.8 (10.4-11.3)
Obese III (40+ kg/m2) 83,363 2,996 (3.6%) 868 (1%) 3,143 (3.8%) 11,438 (13.7%) 57,183 (68.6%) 7,728 (9.3%) 4 (4-4) 65,961 (79.1%) 77,539 (93%) 10.8 (10.4-11.5)
Smoking status
Never and unknown 1,025,213 66,248 (6.5%) 12,026 (1.2%) 36,127 (3.5%) 124,096 (12.1%) 718,480 (70.1%) 68,236 (6.7%) 4 (4-4) 800,765 (78.1%) 928,823 (90.6%) 10.8 (10.4-11.5)
Former 1,124,865 45,276 (4%) 10,955 (1%) 33,880 (3%) 132,482 (11.8%) 801,115 (71.2%) 101,164 (9%) 4 (4-4) 916,524 (81.5%) 1,050,483 (93.4%) 10.8 (10.4-11.3)
Current 259,714 23,093 (8.9%) 3,920 (1.5%) 17,493 (6.7%) 53,837 (20.7%) 146,650 (56.5%) 14,721 (5.7%) 4 (3-4) 164,549 (63.4%) 219,604 (84.6%) 11 (10.4-20.9)
Asthma
No asthma 2,068,059 121,527 (5.9%) 23,387 (1.1%) 75,383 (3.6%) 267,911 (13%) 1,431,087 (69.2%) 148,757 (7.2%) 4 (4-4) 1,607,333 (77.7%) 1,880,886 (90.9%) 10.8 (10.4-11.5)
With no oral steroid use 283,241 11,515 (4.1%) 2,933 (1%) 9,905 (3.5%) 34,741 (12.3%) 196,651 (69.4%) 27,503 (9.7%) 4 (4-4) 227,640 (80.4%) 263,081 (92.9%) 10.8 (10.4-11.3)
With oral steroid use 58,499 1,575 (2.7%) 581 (1%) 2,212 (3.8%) 7,763 (13.3%) 38,500 (65.8%) 7,861 (13.4%) 4 (4-4) 46,865 (80.1%) 54,936 (93.9%) 10.8 (10.1-11.3)
Diabetes
No diabetes 1,808,289 109,060 (6%) 19,957 (1.1%) 61,866 (3.4%) 225,134 (12.5%) 1,263,395 (69.9%) 128,877 (7.1%) 4 (4-4) 1,415,932 (78.3%) 1,644,874 (91%) 10.8 (10.4-11.5)
Controlled 545,342 19,376 (3.6%) 5,908 (1.1%) 22,092 (4.1%) 75,299 (13.8%) 371,630 (68.1%) 51,044 (9.4%) 4 (4-4) 429,695 (78.8%) 507,290 (93%) 10.8 (10.4-11.5)
Not controlled 15,526 560 (3.6%) 161 (1%) 602 (3.9%) 2,450 (15.8%) 10,374 (66.8%) 1,372 (8.8%) 4 (4-4) 11,963 (77.1%) 14,455 (93.1%) 11 (10.4-11.5)
Without recent Hb1ac measure 40,642 5,621 (13.8%) 875 (2.2%) 2,940 (7.2%) 7,532 (18.5%) 20,853 (51.3%) 2,828 (7%) 4 (3-4) 24,241 (59.6%) 32,284 (79.4%) 11 (10.4-21.6)
CKD or RRT
No CKD or RRT 2,179,233 126,462 (5.8%) 24,493 (1.1%) 79,135 (3.6%) 281,057 (12.9%) 1,513,113 (69.4%) 154,980 (7.1%) 4 (4-4) 1,697,143 (77.9%) 1,983,779 (91%) 10.8 (10.4-11.5)
CKD stage 3a 176,036 5,992 (3.4%) 1,771 (1%) 6,118 (3.5%) 21,938 (12.5%) 121,611 (69.1%) 18,613 (10.6%) 4 (4-4) 142,254 (80.8%) 164,773 (93.6%) 10.8 (10.4-11.3)
CKD stage 3b 38,479 1,470 (3.8%) 448 (1.2%) 1,512 (3.9%) 5,243 (13.6%) 24,283 (63.1%) 5,537 (14.4%) 4 (4-4) 30,247 (78.6%) 35,651 (92.7%) 10.8 (10.1-11.5)
CKD stage 4 8,610 406 (4.7%) 105 (1.2%) 420 (4.9%) 1,239 (14.4%) 4,879 (56.7%) 1,561 (18.1%) 4 (3-4) 6,531 (75.9%) 7,833 (91%) 10.8 (10.1-11.5)
CKD stage 5 1,456 77 (5.3%) 21 (1.4%) 98 (6.7%) 252 (17.3%) 700 (48.1%) 308 (21.2%) 4 (3-4) 1,015 (69.7%) 1,295 (88.9%) 10.8 (9.9-20.3)
RRT (dialysis) 3,367 154 (4.6%) 49 (1.5%) 154 (4.6%) 497 (14.8%) 1,330 (39.5%) 1,176 (34.9%) 4 (3-5) 2,478 (73.6%) 3,080 (91.5%) 10.6 (8.1-15.9)
RRT (transplant) 2,611 56 (2.1%) 14 (0.5%) 70 (2.7%) 189 (7.2%) 329 (12.6%) 1,946 (74.5%) 6 (4-7) 2,170 (83.1%) 2,492 (95.4%) 4.1 (3.5-10.6)
Organ transplant
No transplant 2,405,158 134,498 (5.6%) 26,866 (1.1%) 87,374 (3.6%) 310,093 (12.9%) 1,665,643 (69.3%) 180,677 (7.5%) 4 (4-4) 1,877,953 (78.1%) 2,194,486 (91.2%) 10.8 (10.4-11.5)
Kidney transplant 3,171 77 (2.4%) 21 (0.7%) 91 (2.9%) 231 (7.3%) 385 (12.1%) 2,366 (74.6%) 6 (4-7) 2,625 (82.8%) 3,024 (95.4%) 4.1 (3.5-10.8)
Other organ transplant 1,470 42 (2.9%) 14 (1%) 35 (2.4%) 84 (5.7%) 217 (14.8%) 1,085 (73.8%) 6 (4-7) 1,260 (85.7%) 1,393 (94.8%) 4.1 (3.5-10.6)
Hypertension
No 958,076 68,236 (7.1%) 11,928 (1.2%) 35,427 (3.7%) 121,597 (12.7%) 654,360 (68.3%) 66,528 (6.9%) 4 (4-4) 734,531 (76.7%) 859,138 (89.7%) 10.8 (10.4-11.5)
Yes 1,451,723 66,381 (4.6%) 14,973 (1%) 52,073 (3.6%) 188,818 (13%) 1,011,878 (69.7%) 117,593 (8.1%) 4 (4-4) 1,147,307 (79%) 1,339,765 (92.3%) 10.8 (10.4-11.5)
Chronic respiratory disease
No 2,189,236 126,371 (5.8%) 24,605 (1.1%) 78,414 (3.6%) 279,083 (12.7%) 1,530,627 (69.9%) 150,136 (6.9%) 4 (4-4) 1,710,394 (78.1%) 1,995,119 (91.1%) 10.8 (10.4-11.5)
Yes 220,563 8,246 (3.7%) 2,296 (1%) 9,086 (4.1%) 31,332 (14.2%) 135,618 (61.5%) 33,985 (15.4%) 4 (4-4) 171,444 (77.7%) 203,791 (92.4%) 10.8 (10.1-11.5)
Chronic cardiac disease
No 2,081,156 121,821 (5.9%) 23,457 (1.1%) 74,557 (3.6%) 265,496 (12.8%) 1,446,137 (69.5%) 149,695 (7.2%) 4 (4-4) 1,623,671 (78%) 1,894,648 (91%) 10.8 (10.4-11.5)
Yes 328,643 12,796 (3.9%) 3,444 (1%) 12,950 (3.9%) 44,919 (13.7%) 220,108 (67%) 34,426 (10.5%) 4 (4-4) 258,167 (78.6%) 304,255 (92.6%) 10.8 (10.4-11.5)
Cancer (non-haematological)
No 2,138,038 126,406 (5.9%) 24,598 (1.2%) 79,849 (3.7%) 280,980 (13.1%) 1,489,789 (69.7%) 136,423 (6.4%) 4 (4-4) 1,655,451 (77.4%) 1,941,898 (90.8%) 10.8 (10.4-11.5)
Yes 271,761 8,211 (3%) 2,303 (0.8%) 7,658 (2.8%) 29,435 (10.8%) 176,456 (64.9%) 47,698 (17.6%) 4 (4-4) 226,387 (83.3%) 257,005 (94.6%) 10.8 (10.1-11.3)
Haematological malignancy
No 2,381,568 133,840 (5.6%) 26,656 (1.1%) 86,744 (3.6%) 308,189 (12.9%) 1,661,219 (69.8%) 164,920 (6.9%) 4 (4-4) 1,858,017 (78%) 2,172,142 (91.2%) 10.8 (10.4-11.5)
Yes 28,231 777 (2.8%) 245 (0.9%) 763 (2.7%) 2,226 (7.9%) 5,026 (17.8%) 19,201 (68%) 5 (4-6) 23,821 (84.4%) 26,768 (94.8%) 4.4 (3.7-10.8)
Chronic liver disease
No 2,379,804 133,245 (5.6%) 26,516 (1.1%) 86,261 (3.6%) 306,208 (12.9%) 1,649,186 (69.3%) 178,374 (7.5%) 4 (4-4) 1,858,773 (78.1%) 2,171,407 (91.2%) 10.8 (10.4-11.5)
Yes 29,995 1,365 (4.6%) 385 (1.3%) 1,239 (4.1%) 4,207 (14%) 17,052 (56.8%) 5,747 (19.2%) 4 (4-4) 23,065 (76.9%) 27,496 (91.7%) 10.8 (9.9-11.5)
Stroke
No 2,306,745 130,067 (5.6%) 25,578 (1.1%) 83,013 (3.6%) 295,484 (12.8%) 1,600,018 (69.4%) 172,592 (7.5%) 4 (4-4) 1,802,605 (78.1%) 2,104,501 (91.2%) 10.8 (10.4-11.5)
Yes 103,054 4,550 (4.4%) 1,323 (1.3%) 4,494 (4.4%) 14,931 (14.5%) 66,227 (64.3%) 11,529 (11.2%) 4 (4-4) 79,233 (76.9%) 94,402 (91.6%) 10.8 (10.1-11.5)
Dementia
No 2,405,158 134,428 (5.6%) 26,803 (1.1%) 87,220 (3.6%) 309,680 (12.9%) 1,663,963 (69.2%) 183,064 (7.6%) 4 (4-4) 1,878,345 (78.1%) 2,194,682 (91.2%) 10.8 (10.4-11.5)
Yes 4,641 189 (4.1%) 98 (2.1%) 280 (6%) 735 (15.8%) 2,282 (49.2%) 1,057 (22.8%) 4 (3-4) 3,493 (75.3%) 4,221 (91%) 10.6 (9-11.7)
Neurological disease
No 2,370,207 133,252 (5.6%) 26,460 (1.1%) 86,177 (3.6%) 305,802 (12.9%) 1,641,577 (69.3%) 176,946 (7.5%) 4 (4-4) 1,849,456 (78%) 2,161,817 (91.2%) 10.8 (10.4-11.5)
Yes 39,592 1,365 (3.4%) 441 (1.1%) 1,330 (3.4%) 4,613 (11.7%) 24,668 (62.3%) 7,175 (18.1%) 4 (4-4) 32,382 (81.8%) 37,086 (93.7%) 10.8 (9.9-11.3)
Asplenia
No 2,403,695 134,386 (5.6%) 26,831 (1.1%) 87,332 (3.6%) 309,813 (12.9%) 1,663,809 (69.2%) 181,517 (7.6%) 4 (4-4) 1,876,791 (78.1%) 2,193,184 (91.2%) 10.8 (10.4-11.5)
Yes 6,104 224 (3.7%) 70 (1.1%) 168 (2.8%) 602 (9.9%) 2,429 (39.8%) 2,611 (42.8%) 4 (4-5) 5,047 (82.7%) 5,719 (93.7%) 10.6 (4.4-11.3)
Rheumatoid arthritis, lupus, or psoriasis
No 2,226,959 128,212 (5.8%) 25,165 (1.1%) 81,410 (3.7%) 287,707 (12.9%) 1,560,090 (70.1%) 144,368 (6.5%) 4 (4-4) 1,734,845 (77.9%) 2,027,956 (91.1%) 10.8 (10.4-11.5)
Yes 182,840 6,398 (3.5%) 1,736 (0.9%) 6,097 (3.3%) 22,708 (12.4%) 106,155 (58.1%) 39,753 (21.7%) 4 (4-4) 146,993 (80.4%) 170,954 (93.5%) 10.8 (9.9-11.3)
Immunodeficiency
No 2,352,119 132,832 (5.6%) 26,397 (1.1%) 85,799 (3.6%) 305,270 (13%) 1,651,937 (70.2%) 149,891 (6.4%) 4 (4-4) 1,833,895 (78%) 2,144,534 (91.2%) 10.8 (10.4-11.5)
Yes 57,680 1,785 (3.1%) 504 (0.9%) 1,708 (3%) 5,145 (8.9%) 14,308 (24.8%) 34,230 (59.3%) 5 (4-6) 47,943 (83.1%) 54,376 (94.3%) 8.3 (3.7-11)
Learning disability
No 2,401,000 134,246 (5.6%) 26,775 (1.1%) 87,080 (3.6%) 309,218 (12.9%) 1,661,576 (69.2%) 182,105 (7.6%) 4 (4-4) 1,874,943 (78.1%) 2,190,860 (91.2%) 10.8 (10.4-11.5)
Yes 8,799 371 (4.2%) 126 (1.4%) 420 (4.8%) 1,197 (13.6%) 4,669 (53.1%) 2,016 (22.9%) 4 (4-4) 6,895 (78.4%) 8,043 (91.4%) 10.6 (9.4-11.3)
Severe mental illness
No 2,377,858 131,852 (5.5%) 26,264 (1.1%) 85,526 (3.6%) 305,130 (12.8%) 1,648,647 (69.3%) 180,439 (7.6%) 4 (4-4) 1,859,886 (78.2%) 2,171,568 (91.3%) 10.8 (10.4-11.5)
Yes 31,941 2,758 (8.6%) 637 (2%) 1,974 (6.2%) 5,285 (16.5%) 17,598 (55.1%) 3,682 (11.5%) 4 (3-4) 21,952 (68.7%) 27,335 (85.6%) 10.8 (10.1-20.5)


Abbreviations: CKD = chronic kidney disease; IMD = index of multiple deprivation; IQR = interquartile range; RRT = renal replacement therapy.


50-64y population: Vaccination history by demographic and clinical subgroups

Show/hide table

Level N Dose count Dose count, median (IQR) Vaccinated in past 12 months, n (%) Vaccinated in past 24 months, n (%) Time in months since last dose, median (IQR)
0 1 2 3 4 5+
Sex
Female 2,406,194 202,475 (8.4%) 39,284 (1.6%) 192,990 (8%) 641,655 (26.7%) 1,241,814 (51.6%) 87,976 (3.7%) 4 (3-4) 1,359,155 (56.5%) 2,035,159 (84.6%) 11 (10.1-20.9)
Male 2,455,138 299,292 (12.2%) 43,078 (1.8%) 212,457 (8.7%) 695,989 (28.3%) 1,141,231 (46.5%) 63,084 (2.6%) 3 (3-4) 1,235,584 (50.3%) 1,966,615 (80.1%) 11.5 (10.1-21.2)
Ethnicity (broad categories)
White 4,063,297 328,370 (8.1%) 63,014 (1.6%) 290,717 (7.2%) 1,094,338 (26.9%) 2,146,228 (52.8%) 140,637 (3.5%) 4 (3-4) 2,336,656 (57.5%) 3,471,174 (85.4%) 10.8 (10.1-20.7)
Mixed 47,082 9,926 (21.1%) 1,344 (2.9%) 6,342 (13.5%) 13,482 (28.6%) 14,868 (31.6%) 1,120 (2.4%) 3 (2-4) 16,793 (35.7%) 32,025 (68%) 20.5 (10.6-27.2)
South Asian 270,998 35,112 (13%) 6,951 (2.6%) 50,827 (18.8%) 99,470 (36.7%) 74,487 (27.5%) 4,158 (1.5%) 3 (2-4) 82,586 (30.5%) 194,964 (71.9%) 20.5 (10.8-25.8)
Black 126,063 33,537 (26.6%) 4,228 (3.4%) 24,367 (19.3%) 35,189 (27.9%) 26,376 (20.9%) 2,366 (1.9%) 3 (0-3) 30,989 (24.6%) 73,549 (58.3%) 21.4 (13.6-36)
Other 93,800 23,576 (25.1%) 2,926 (3.1%) 11,536 (12.3%) 25,949 (27.7%) 28,357 (30.2%) 1,456 (1.6%) 3 (0-4) 31,745 (33.8%) 61,117 (65.2%) 20.5 (10.6-36)
Unknown 260,092 71,246 (27.4%) 3,906 (1.5%) 21,651 (8.3%) 69,216 (26.6%) 92,736 (35.7%) 1,330 (0.5%) 3 (0-4) 95,977 (36.9%) 168,938 (65%) 20.5 (10.4-36)
Ethnicity (narrow categories)
British or Mixed British 3,690,092 230,293 (6.2%) 54,649 (1.5%) 247,044 (6.7%) 997,430 (27%) 2,027,459 (54.9%) 133,217 (3.6%) 4 (3-4) 2,206,134 (59.8%) 3,233,223 (87.6%) 10.8 (9.9-20.7)
Irish 27,748 3,374 (12.2%) 665 (2.4%) 2,240 (8.1%) 7,511 (27.1%) 13,041 (47%) 917 (3.3%) 4 (3-4) 14,497 (52.2%) 22,400 (80.7%) 11.3 (10.1-21.4)
Other White 345,534 94,717 (27.4%) 7,700 (2.2%) 41,405 (12%) 89,446 (25.9%) 105,742 (30.6%) 6,517 (1.9%) 3 (0-4) 116,046 (33.6%) 215,628 (62.4%) 20.7 (10.6-36)
White + Black Caribbean 10,948 2,653 (24.2%) 343 (3.1%) 1,589 (14.5%) 3,024 (27.6%) 3,087 (28.2%) 252 (2.3%) 3 (1-4) 3,493 (31.9%) 6,944 (63.4%) 20.7 (10.8-29.2)
White + Black African 9,793 2,114 (21.6%) 322 (3.3%) 1,687 (17.2%) 2,940 (30%) 2,513 (25.7%) 217 (2.2%) 3 (2-4) 2,926 (29.9%) 6,412 (65.5%) 20.7 (10.8-27.4)
White + Asian 8,855 1,246 (14.1%) 203 (2.3%) 896 (10.1%) 2,625 (29.6%) 3,647 (41.2%) 238 (2.7%) 3 (2-4) 4,032 (45.5%) 6,867 (77.5%) 19.6 (10.1-22.3)
Other mixed 17,500 3,913 (22.4%) 476 (2.7%) 2,177 (12.4%) 4,893 (28%) 5,635 (32.2%) 406 (2.3%) 3 (1-4) 6,342 (36.2%) 11,809 (67.5%) 20.5 (10.4-27.4)
Indian or British Indian 116,760 13,419 (11.5%) 2,632 (2.3%) 14,686 (12.6%) 44,072 (37.7%) 39,543 (33.9%) 2,408 (2.1%) 3 (2-4) 43,442 (37.2%) 90,972 (77.9%) 20.3 (10.6-22.3)
Pakistani or British Pakistani 72,345 10,402 (14.4%) 2,226 (3.1%) 24,122 (33.3%) 25,578 (35.4%) 9,492 (13.1%) 525 (0.7%) 2 (2-3) 10,962 (15.2%) 43,043 (59.5%) 21.4 (19.8-27.2)
Bangladeshi or British Bangladeshi 16,744 1,610 (9.6%) 413 (2.5%) 3,192 (19.1%) 7,294 (43.6%) 4,081 (24.4%) 154 (0.9%) 3 (2-4) 4,529 (27%) 12,425 (74.2%) 20.5 (11-24.6)
Other Asian 65,149 9,674 (14.8%) 1,680 (2.6%) 8,827 (13.5%) 22,533 (34.6%) 21,371 (32.8%) 1,071 (1.6%) 3 (2-4) 23,653 (36.3%) 48,531 (74.5%) 20.5 (10.6-24.6)
Caribbean 33,145 10,983 (33.1%) 1,092 (3.3%) 5,614 (16.9%) 8,127 (24.5%) 6,699 (20.2%) 630 (1.9%) 2 (0-3) 7,735 (23.3%) 17,507 (52.8%) 22.1 (17.3-36)
African 60,081 14,315 (23.8%) 2,058 (3.4%) 12,733 (21.2%) 18,039 (30%) 11,844 (19.7%) 1,085 (1.8%) 3 (1-3) 14,196 (23.6%) 36,197 (60.2%) 21.2 (15.9-28.8)
Other Black 32,837 8,232 (25.1%) 1,071 (3.3%) 6,027 (18.4%) 9,016 (27.5%) 7,833 (23.9%) 651 (2%) 3 (0-4) 9,058 (27.6%) 19,831 (60.4%) 20.9 (11-36)
Chinese 25,354 5,831 (23%) 924 (3.6%) 1,876 (7.4%) 6,160 (24.3%) 10,129 (40%) 434 (1.7%) 3 (1-4) 11,480 (45.3%) 18,368 (72.4%) 19.3 (10.1-26.7)
Other 68,446 17,738 (25.9%) 2,002 (2.9%) 9,667 (14.1%) 19,782 (28.9%) 18,235 (26.6%) 1,022 (1.5%) 3 (0-4) 20,272 (29.6%) 42,756 (62.5%) 20.7 (10.8-36)
Unknown 260,015 71,239 (27.4%) 3,906 (1.5%) 21,672 (8.3%) 69,174 (26.6%) 92,701 (35.7%) 1,323 (0.5%) 3 (0-4) 95,935 (36.9%) 168,854 (64.9%) 20.5 (10.4-36)
IMD quintile
5 (least deprived) 978,208 62,671 (6.4%) 11,361 (1.2%) 47,698 (4.9%) 238,105 (24.3%) 584,766 (59.8%) 33,600 (3.4%) 4 (3-4) 629,573 (64.4%) 874,965 (89.4%) 10.6 (9.9-20.5)
4 1,050,189 85,897 (8.2%) 15,211 (1.4%) 65,268 (6.2%) 275,079 (26.2%) 573,937 (54.7%) 34,797 (3.3%) 4 (3-4) 622,363 (59.3%) 907,865 (86.4%) 10.8 (9.9-20.7)
3 1,044,197 102,585 (9.8%) 17,248 (1.7%) 79,380 (7.6%) 287,483 (27.5%) 523,747 (50.2%) 33,754 (3.2%) 4 (3-4) 571,242 (54.7%) 872,032 (83.5%) 11 (10.1-20.9)
2 923,398 114,310 (12.4%) 17,724 (1.9%) 94,255 (10.2%) 272,405 (29.5%) 397,649 (43.1%) 27,055 (2.9%) 3 (3-4) 436,366 (47.3%) 725,522 (78.6%) 19.1 (10.1-21.9)
1 (most deprived) 865,340 136,311 (15.8%) 20,825 (2.4%) 118,839 (13.7%) 264,572 (30.6%) 302,939 (35%) 21,854 (2.5%) 3 (2-4) 335,195 (38.7%) 621,383 (71.8%) 20.5 (10.4-26.2)
Body Mass Index
Not obese 3,595,697 425,075 (11.8%) 63,014 (1.8%) 306,341 (8.5%) 1,002,015 (27.9%) 1,701,525 (47.3%) 97,720 (2.7%) 4 (3-4) 1,842,799 (51.3%) 2,899,715 (80.6%) 11.3 (10.1-21.2)
Obese I (30-34.9 kg/m2) 735,462 46,557 (6.3%) 11,403 (1.6%) 58,681 (8%) 200,536 (27.3%) 389,830 (53%) 28,455 (3.9%) 4 (3-4) 428,225 (58.2%) 637,973 (86.7%) 10.8 (10.1-20.7)
Obese II (35-39.9 kg/m2) 320,922 18,550 (5.8%) 4,816 (1.5%) 24,724 (7.7%) 84,329 (26.3%) 174,321 (54.3%) 14,182 (4.4%) 4 (3-4) 192,843 (60.1%) 280,630 (87.4%) 10.8 (10.1-20.7)
Obese III (40+ kg/m2) 209,258 11,585 (5.5%) 3,129 (1.5%) 15,701 (7.5%) 50,757 (24.3%) 117,376 (56.1%) 10,703 (5.1%) 4 (3-4) 130,872 (62.5%) 183,456 (87.7%) 10.8 (10.1-20.7)
Smoking status
Never and unknown 2,245,432 232,932 (10.4%) 33,208 (1.5%) 163,814 (7.3%) 576,702 (25.7%) 1,172,038 (52.2%) 66,738 (3%) 4 (3-4) 1,267,707 (56.5%) 1,875,706 (83.5%) 10.8 (10.1-20.9)
Former 1,807,764 137,095 (7.6%) 26,558 (1.5%) 131,866 (7.3%) 498,176 (27.6%) 945,609 (52.3%) 68,453 (3.8%) 4 (3-4) 1,036,126 (57.3%) 1,554,063 (86%) 10.8 (10.1-20.7)
Current 808,129 131,733 (16.3%) 22,603 (2.8%) 109,767 (13.6%) 262,766 (32.5%) 265,398 (32.8%) 15,869 (2%) 3 (2-4) 290,913 (36%) 572,005 (70.8%) 20.5 (10.4-26.5)
Asthma
No asthma 4,100,628 448,483 (10.9%) 70,154 (1.7%) 347,543 (8.5%) 1,142,561 (27.9%) 1,975,834 (48.2%) 116,053 (2.8%) 4 (3-4) 2,143,428 (52.3%) 3,346,756 (81.6%) 11.3 (10.1-21.2)
With no oral steroid use 654,115 47,950 (7.3%) 10,458 (1.6%) 49,273 (7.5%) 168,084 (25.7%) 350,714 (53.6%) 27,636 (4.2%) 4 (3-4) 386,428 (59.1%) 561,736 (85.9%) 10.8 (10.1-20.7)
With oral steroid use 106,589 5,334 (5%) 1,757 (1.6%) 8,624 (8.1%) 26,999 (25.3%) 56,497 (53%) 7,371 (6.9%) 4 (3-4) 64,883 (60.9%) 93,275 (87.5%) 10.8 (10.1-20.7)
Diabetes
No diabetes 4,100,187 448,980 (11%) 69,300 (1.7%) 334,768 (8.2%) 1,138,830 (27.8%) 1,993,012 (48.6%) 115,290 (2.8%) 4 (3-4) 2,158,366 (52.6%) 3,355,198 (81.8%) 11 (10.1-21.2)
Controlled 656,768 39,606 (6%) 10,570 (1.6%) 58,793 (9%) 168,777 (25.7%) 346,850 (52.8%) 32,172 (4.9%) 4 (3-4) 388,241 (59.1%) 566,069 (86.2%) 11 (10.1-20.9)
Not controlled 22,246 1,260 (5.7%) 336 (1.5%) 1,708 (7.7%) 6,020 (27.1%) 11,900 (53.5%) 1,015 (4.6%) 4 (3-4) 13,251 (59.6%) 19,460 (87.5%) 11 (10.4-20.9)
Without recent Hb1ac measure 82,131 11,914 (14.5%) 2,156 (2.6%) 10,178 (12.4%) 24,017 (29.2%) 31,276 (38.1%) 2,583 (3.1%) 3 (2-4) 34,888 (42.5%) 61,047 (74.3%) 20.3 (10.4-25.1)
CKD or RRT
No CKD or RRT 4,750,508 494,326 (10.4%) 80,556 (1.7%) 396,956 (8.4%) 1,312,115 (27.6%) 2,328,053 (49%) 138,502 (2.9%) 4 (3-4) 2,526,307 (53.2%) 3,905,846 (82.2%) 11 (10.1-21.2)
CKD stage 3a 82,250 5,467 (6.6%) 1,316 (1.6%) 6,356 (7.7%) 19,586 (23.8%) 43,575 (53%) 5,957 (7.2%) 4 (3-4) 50,596 (61.5%) 71,281 (86.7%) 10.8 (10.1-20.7)
CKD stage 3b 13,524 994 (7.3%) 231 (1.7%) 1,050 (7.8%) 3,136 (23.2%) 6,601 (48.8%) 1,505 (11.1%) 4 (3-4) 8,225 (60.8%) 11,578 (85.6%) 10.8 (10.1-20.9)
CKD stage 4 4,396 329 (7.5%) 91 (2.1%) 371 (8.4%) 1,015 (23.1%) 2,023 (46%) 560 (12.7%) 4 (3-4) 2,632 (59.9%) 3,731 (84.9%) 10.8 (10.1-20.9)
CKD stage 5 1,169 112 (9.6%) 28 (2.4%) 112 (9.6%) 266 (22.8%) 476 (40.7%) 168 (14.4%) 4 (3-4) 665 (56.9%) 945 (80.8%) 11 (9.9-21.4)
RRT (dialysis) 4,445 308 (6.9%) 84 (1.9%) 350 (7.9%) 910 (20.5%) 1,491 (33.5%) 1,302 (29.3%) 4 (3-5) 2,688 (60.5%) 3,815 (85.8%) 10.8 (9.3-20.7)
RRT (transplant) 5,040 224 (4.4%) 63 (1.2%) 252 (5%) 616 (12.2%) 826 (16.4%) 3,066 (60.8%) 5 (4-6) 3,626 (71.9%) 4,578 (90.8%) 9.4 (3.5-15.2)
Organ transplant
No transplant 4,853,184 501,410 (10.3%) 82,271 (1.7%) 405,055 (8.3%) 1,336,615 (27.5%) 2,381,694 (49.1%) 146,146 (3%) 4 (3-4) 2,588,887 (53.3%) 3,994,354 (82.3%) 11 (10.1-21.2)
Kidney transplant 6,188 273 (4.4%) 77 (1.2%) 301 (4.9%) 784 (12.7%) 1,001 (16.2%) 3,752 (60.6%) 5 (4-6) 4,410 (71.3%) 5,628 (91%) 9.4 (3.5-15.6)
Other organ transplant 1,960 84 (4.3%) 21 (1.1%) 91 (4.6%) 252 (12.9%) 343 (17.5%) 1,162 (59.3%) 5 (4-6) 1,442 (73.6%) 1,792 (91.4%) 8.5 (3.5-14)
Hypertension
No 2,817,367 336,077 (11.9%) 50,057 (1.8%) 239,092 (8.5%) 783,706 (27.8%) 1,331,974 (47.3%) 76,461 (2.7%) 3 (3-4) 1,443,995 (51.3%) 2,271,815 (80.6%) 11.3 (10.1-21.2)
Yes 2,043,965 165,690 (8.1%) 32,312 (1.6%) 166,348 (8.1%) 553,938 (27.1%) 1,051,071 (51.4%) 74,599 (3.6%) 4 (3-4) 1,150,744 (56.3%) 1,729,959 (84.6%) 11 (10.1-20.9)
Chronic respiratory disease
No 4,669,588 487,557 (10.4%) 78,309 (1.7%) 387,457 (8.3%) 1,289,337 (27.6%) 2,291,681 (49.1%) 135,254 (2.9%) 4 (3-4) 2,485,392 (53.2%) 3,841,824 (82.3%) 11 (10.1-21.2)
Yes 191,737 14,203 (7.4%) 4,060 (2.1%) 17,990 (9.4%) 48,307 (25.2%) 91,364 (47.7%) 15,806 (8.2%) 4 (3-4) 109,347 (57%) 159,950 (83.4%) 11 (10.1-21.2)
Chronic cardiac disease
No 4,580,149 481,747 (10.5%) 77,448 (1.7%) 381,325 (8.3%) 1,267,231 (27.7%) 2,236,500 (48.8%) 135,891 (3%) 4 (3-4) 2,429,476 (53%) 3,763,025 (82.2%) 11 (10.1-21.2)
Yes 281,183 20,020 (7.1%) 4,921 (1.8%) 24,122 (8.6%) 70,413 (25%) 146,545 (52.1%) 15,169 (5.4%) 4 (3-4) 165,263 (58.8%) 238,742 (84.9%) 11 (10.1-20.9)
Cancer (non-haematological)
No 4,626,048 488,432 (10.6%) 79,289 (1.7%) 391,055 (8.5%) 1,284,717 (27.8%) 2,260,265 (48.9%) 122,283 (2.6%) 4 (3-4) 2,441,964 (52.8%) 3,792,614 (82%) 11 (10.1-21.2)
Yes 235,284 13,335 (5.7%) 3,080 (1.3%) 14,392 (6.1%) 52,927 (22.5%) 122,780 (52.2%) 28,777 (12.2%) 4 (3-4) 152,782 (64.9%) 209,160 (88.9%) 10.6 (9.9-20.5)
Haematological malignancy
No 4,834,088 500,241 (10.3%) 81,991 (1.7%) 403,907 (8.4%) 1,333,220 (27.6%) 2,376,689 (49.2%) 138,040 (2.9%) 4 (3-4) 2,576,007 (53.3%) 3,977,386 (82.3%) 11 (10.1-21.2)
Yes 27,244 1,526 (5.6%) 378 (1.4%) 1,540 (5.7%) 4,424 (16.2%) 6,356 (23.3%) 13,020 (47.8%) 4 (3-6) 18,732 (68.8%) 24,388 (89.5%) 10.1 (3.7-19.8)
Chronic liver disease
No 4,813,053 497,259 (10.3%) 80,983 (1.7%) 400,603 (8.3%) 1,325,506 (27.5%) 2,362,801 (49.1%) 145,901 (3%) 4 (3-4) 2,568,678 (53.4%) 3,962,574 (82.3%) 11 (10.1-21.2)
Yes 48,279 4,508 (9.3%) 1,379 (2.9%) 4,844 (10%) 12,138 (25.1%) 20,244 (41.9%) 5,159 (10.7%) 4 (3-4) 26,061 (54%) 39,200 (81.2%) 11 (10.1-21.4)
Stroke
No 4,776,366 495,131 (10.4%) 80,605 (1.7%) 397,859 (8.3%) 1,316,644 (27.6%) 2,340,387 (49%) 145,740 (3.1%) 4 (3-4) 2,545,466 (53.3%) 3,930,591 (82.3%) 11 (10.1-21.2)
Yes 84,966 6,636 (7.8%) 1,764 (2.1%) 7,588 (8.9%) 21,000 (24.7%) 42,658 (50.2%) 5,320 (6.3%) 4 (3-4) 49,273 (58%) 71,183 (83.8%) 11 (10.1-21.2)
Neurological disease
No 4,812,409 498,897 (10.4%) 81,634 (1.7%) 402,500 (8.4%) 1,328,138 (27.6%) 2,356,781 (49%) 144,459 (3%) 4 (3-4) 2,561,328 (53.2%) 3,958,409 (82.3%) 11 (10.1-21.2)
Yes 48,923 2,870 (5.9%) 735 (1.5%) 2,940 (6%) 9,513 (19.4%) 26,264 (53.7%) 6,608 (13.5%) 4 (3-4) 33,411 (68.3%) 43,365 (88.6%) 10.8 (9.9-20.5)
Asplenia
No 4,851,378 500,997 (10.3%) 82,215 (1.7%) 404,782 (8.3%) 1,335,810 (27.5%) 2,379,195 (49%) 148,372 (3.1%) 4 (3-4) 2,588,236 (53.4%) 3,993,185 (82.3%) 11 (10.1-21.2)
Yes 9,947 770 (7.7%) 154 (1.5%) 658 (6.6%) 1,834 (18.4%) 3,850 (38.7%) 2,688 (27%) 4 (3-5) 6,503 (65.4%) 8,582 (86.3%) 10.8 (9.9-20.7)
Rheumatoid arthritis, lupus, or psoriasis
No 4,563,405 482,090 (10.6%) 77,917 (1.7%) 382,732 (8.4%) 1,260,161 (27.6%) 2,245,397 (49.2%) 115,115 (2.5%) 4 (3-4) 2,419,690 (53%) 3,744,146 (82%) 11 (10.1-21.2)
Yes 297,927 19,677 (6.6%) 4,452 (1.5%) 22,715 (7.6%) 77,490 (26%) 137,648 (46.2%) 35,945 (12.1%) 4 (3-4) 175,049 (58.8%) 257,628 (86.5%) 10.8 (9.9-20.7)
Immunodeficiency
No 4,787,615 496,951 (10.4%) 81,200 (1.7%) 400,372 (8.4%) 1,324,316 (27.7%) 2,363,256 (49.4%) 121,520 (2.5%) 4 (3-4) 2,546,586 (53.2%) 3,937,276 (82.2%) 11 (10.1-21.2)
Yes 73,717 4,816 (6.5%) 1,169 (1.6%) 5,068 (6.9%) 13,328 (18.1%) 19,789 (26.8%) 29,540 (40.1%) 4 (3-5) 48,153 (65.3%) 64,498 (87.5%) 10.4 (4.1-20.5)
Learning disability
No 4,834,690 500,388 (10.3%) 81,893 (1.7%) 403,900 (8.4%) 1,332,975 (27.6%) 2,368,030 (49%) 147,511 (3.1%) 4 (3-4) 2,575,517 (53.3%) 3,977,939 (82.3%) 11 (10.1-21.2)
Yes 26,642 1,379 (5.2%) 476 (1.8%) 1,547 (5.8%) 4,669 (17.5%) 15,015 (56.4%) 3,556 (13.3%) 4 (3-4) 19,222 (72.1%) 23,835 (89.5%) 10.6 (9.9-19.6)
Severe mental illness
No 4,785,382 491,176 (10.3%) 79,926 (1.7%) 397,124 (8.3%) 1,319,185 (27.6%) 2,350,796 (49.1%) 147,175 (3.1%) 4 (3-4) 2,556,946 (53.4%) 3,944,136 (82.4%) 11 (10.1-21.2)
Yes 75,950 10,591 (13.9%) 2,443 (3.2%) 8,323 (11%) 18,459 (24.3%) 32,249 (42.5%) 3,885 (5.1%) 3 (2-4) 37,793 (49.8%) 57,631 (75.9%) 13.3 (10.4-22.6)


Abbreviations: CKD = chronic kidney disease; IMD = index of multiple deprivation; IQR = interquartile range; RRT = renal replacement therapy.


18-49y population: Vaccination history by demographic and clinical subgroups

Show/hide table

Level N Dose count Dose count, median (IQR) Vaccinated in past 12 months, n (%) Vaccinated in past 24 months, n (%) Time in months since last dose, median (IQR)
0 1 2 3 4 5+
Sex
Female 4,905,887 1,186,052 (24.2%) 225,575 (4.6%) 978,852 (20%) 2,042,649 (41.6%) 438,277 (8.9%) 34,482 (0.7%) 3 (1-3) 537,383 (11%) 3,163,314 (64.5%) 20.7 (19.8-28.8)
Male 5,187,819 1,635,298 (31.5%) 252,000 (4.9%) 1,084,594 (20.9%) 1,945,041 (37.5%) 248,052 (4.8%) 22,841 (0.4%) 2 (0-3) 322,441 (6.2%) 2,941,995 (56.7%) 21.6 (20-36)
Ethnicity (broad categories)
White 7,212,779 1,696,093 (23.5%) 320,103 (4.4%) 1,408,596 (19.5%) 3,153,976 (43.7%) 582,526 (8.1%) 51,485 (0.7%) 3 (1-3) 705,474 (9.8%) 4,678,149 (64.9%) 20.5 (19.8-27.8)
Mixed 209,874 84,497 (40.3%) 12,544 (6%) 44,205 (21.1%) 58,457 (27.9%) 9,408 (4.5%) 756 (0.4%) 2 (0-3) 13,398 (6.4%) 102,795 (49%) 24.4 (20.3-36)
South Asian 1,105,636 371,301 (33.6%) 61,600 (5.6%) 294,056 (26.6%) 327,656 (29.6%) 48,265 (4.4%) 2,758 (0.2%) 2 (0-3) 70,798 (6.4%) 582,946 (52.7%) 23.5 (20-36)
Black 367,157 180,264 (49.1%) 23,842 (6.5%) 87,745 (23.9%) 64,344 (17.5%) 10,087 (2.7%) 882 (0.2%) 1 (0-2) 19,117 (5.2%) 145,733 (39.7%) 28.5 (20.5-36)
Other 407,330 190,085 (46.7%) 25,592 (6.3%) 70,112 (17.2%) 105,735 (26%) 14,917 (3.7%) 889 (0.2%) 1 (0-3) 21,861 (5.4%) 178,787 (43.9%) 26.2 (20.3-36)
Unknown 790,930 299,110 (37.8%) 33,894 (4.3%) 158,732 (20.1%) 277,522 (35.1%) 21,119 (2.7%) 553 (0.1%) 2 (0-3) 29,162 (3.7%) 416,906 (52.7%) 23.5 (20.3-36)
Ethnicity (narrow categories)
British or Mixed British 5,901,651 1,044,981 (17.7%) 270,298 (4.6%) 1,174,768 (19.9%) 2,822,253 (47.8%) 541,261 (9.2%) 48,090 (0.8%) 3 (2-3) 653,128 (11.1%) 4,165,637 (70.6%) 20.5 (19.8-25.3)
Irish 45,430 15,855 (34.9%) 2,212 (4.9%) 6,951 (15.3%) 16,849 (37.1%) 3,276 (7.2%) 280 (0.6%) 2 (0-3) 4,060 (8.9%) 25,032 (55.1%) 21.6 (20.3-36)
Other White 1,265,719 635,229 (50.2%) 47,593 (3.8%) 226,919 (17.9%) 314,860 (24.9%) 38,003 (3%) 3,122 (0.2%) 0 (0-3) 48,307 (3.8%) 487,494 (38.5%) 36 (20.5-36)
White + Black Caribbean 45,647 20,762 (45.5%) 2,828 (6.2%) 9,744 (21.3%) 10,514 (23%) 1,680 (3.7%) 126 (0.3%) 1 (0-3) 2,366 (5.2%) 19,740 (43.2%) 26.7 (20.3-36)
White + Black African 40,390 17,318 (42.9%) 2,618 (6.5%) 9,534 (23.6%) 9,352 (23.2%) 1,463 (3.6%) 112 (0.3%) 2 (0-3) 2,464 (6.1%) 18,487 (45.8%) 25.1 (20.3-36)
White + Asian 43,456 13,692 (31.5%) 2,520 (5.8%) 8,757 (20.2%) 15,617 (35.9%) 2,660 (6.1%) 210 (0.5%) 2 (0-3) 3,633 (8.4%) 25,389 (58.4%) 21.2 (19.8-36)
Other mixed 80,367 32,718 (40.7%) 4,571 (5.7%) 16,184 (20.1%) 22,974 (28.6%) 3,612 (4.5%) 308 (0.4%) 2 (0-3) 4,942 (6.1%) 39,172 (48.7%) 24.4 (20.3-36)
Indian or British Indian 455,371 162,960 (35.8%) 22,799 (5%) 89,418 (19.6%) 155,050 (34%) 23,730 (5.2%) 1,407 (0.3%) 2 (0-3) 32,697 (7.2%) 244,853 (53.8%) 22.8 (20-36)
Pakistani or British Pakistani 320,306 97,951 (30.6%) 19,579 (6.1%) 126,077 (39.4%) 69,041 (21.6%) 7,196 (2.2%) 462 (0.1%) 2 (0-2) 13,580 (4.2%) 159,670 (49.8%) 24.2 (20.3-36)
Bangladeshi or British Bangladeshi 81,816 22,946 (28%) 4,564 (5.6%) 24,269 (29.7%) 26,502 (32.4%) 3,360 (4.1%) 168 (0.2%) 2 (0-3) 4,844 (5.9%) 46,109 (56.4%) 22.3 (20-36)
Other Asian 248,129 87,430 (35.2%) 14,658 (5.9%) 54,306 (21.9%) 77,035 (31%) 13,979 (5.6%) 714 (0.3%) 2 (0-3) 19,684 (7.9%) 132,286 (53.3%) 23 (20-36)
Caribbean 48,916 27,517 (56.3%) 2,562 (5.2%) 9,772 (20%) 7,637 (15.6%) 1,295 (2.6%) 133 (0.3%) 0 (0-2) 1,974 (4%) 16,576 (33.9%) 36 (20.9-36)
African 228,235 107,807 (47.2%) 15,323 (6.7%) 57,274 (25.1%) 41,020 (18%) 6,272 (2.7%) 532 (0.2%) 1 (0-2) 12,341 (5.4%) 93,709 (41.1%) 27.2 (20.5-36)
Other Black 90,020 44,954 (49.9%) 5,957 (6.6%) 20,699 (23%) 15,680 (17.4%) 2,520 (2.8%) 217 (0.2%) 1 (0-2) 4,809 (5.3%) 35,455 (39.4%) 30.4 (20.5-36)
Chinese 124,768 61,684 (49.4%) 9,842 (7.9%) 13,342 (10.7%) 34,720 (27.8%) 4,907 (3.9%) 273 (0.2%) 1 (0-3) 7,448 (6%) 56,952 (45.6%) 27.2 (20.3-36)
Other 282,611 128,436 (45.4%) 15,743 (5.6%) 56,749 (20.1%) 71,036 (25.1%) 10,024 (3.5%) 616 (0.2%) 1 (0-3) 14,413 (5.1%) 121,877 (43.1%) 26 (20.3-36)
Unknown 790,881 299,110 (37.8%) 33,901 (4.3%) 158,683 (20.1%) 277,543 (35.1%) 21,091 (2.7%) 553 (0.1%) 2 (0-3) 29,141 (3.7%) 416,878 (52.7%) 23.5 (20.3-36)
IMD quintile
5 (least deprived) 1,627,087 299,768 (18.4%) 58,198 (3.6%) 268,961 (16.5%) 841,463 (51.7%) 146,083 (9%) 12,614 (0.8%) 3 (2-3) 176,176 (10.8%) 1,189,496 (73.1%) 20.5 (19.8-24.6)
4 1,893,934 424,200 (22.4%) 77,483 (4.1%) 345,905 (18.3%) 882,168 (46.6%) 151,179 (8%) 12,992 (0.7%) 3 (1-3) 184,989 (9.8%) 1,282,722 (67.7%) 20.5 (19.8-26.7)
3 2,086,112 556,710 (26.7%) 94,248 (4.5%) 411,586 (19.7%) 862,904 (41.4%) 147,945 (7.1%) 12,712 (0.6%) 2 (0-3) 184,877 (8.9%) 1,299,977 (62.3%) 20.7 (20-36)
2 2,177,028 688,870 (31.6%) 110,600 (5.1%) 475,566 (21.8%) 762,111 (35%) 129,276 (5.9%) 10,605 (0.5%) 2 (0-3) 165,515 (7.6%) 1,213,681 (55.7%) 22.1 (20-36)
1 (most deprived) 2,309,552 851,802 (36.9%) 137,053 (5.9%) 561,421 (24.3%) 639,044 (27.7%) 111,846 (4.8%) 8,393 (0.4%) 2 (0-3) 148,260 (6.4%) 1,119,440 (48.5%) 24.4 (20.3-36)
Body Mass Index
Not obese 8,639,274 2,580,928 (29.9%) 419,671 (4.9%) 1,777,174 (20.6%) 3,357,564 (38.9%) 464,345 (5.4%) 39,592 (0.5%) 2 (0-3) 600,677 (7%) 5,084,779 (58.9%) 21.2 (20-36)
Obese I (30-34.9 kg/m2) 799,386 144,599 (18.1%) 32,599 (4.1%) 161,315 (20.2%) 360,549 (45.1%) 91,847 (11.5%) 8,470 (1.1%) 3 (2-3) 110,054 (13.8%) 549,556 (68.7%) 20.5 (19.8-26)
Obese II (35-39.9 kg/m2) 369,222 57,946 (15.7%) 14,539 (3.9%) 73,129 (19.8%) 164,367 (44.5%) 54,516 (14.8%) 4,725 (1.3%) 3 (2-3) 63,980 (17.3%) 261,884 (70.9%) 20.5 (19.3-25.3)
Obese III (40+ kg/m2) 285,824 37,870 (13.2%) 10,773 (3.8%) 51,828 (18.1%) 105,203 (36.8%) 75,614 (26.5%) 4,536 (1.6%) 3 (2-4) 85,113 (29.8%) 209,097 (73.2%) 20.5 (11-25.1)
Smoking status
Never and unknown 5,989,844 1,659,343 (27.7%) 279,181 (4.7%) 1,208,291 (20.2%) 2,413,481 (40.3%) 397,257 (6.6%) 32,291 (0.5%) 2 (0-3) 507,990 (8.5%) 3,746,232 (62.5%) 20.7 (19.8-36)
Former 2,280,481 478,667 (21%) 85,673 (3.8%) 434,294 (19%) 1,046,787 (45.9%) 215,460 (9.4%) 19,593 (0.9%) 3 (2-3) 256,354 (11.2%) 1,508,563 (66.2%) 20.5 (19.8-26.9)
Current 1,823,381 683,340 (37.5%) 112,728 (6.2%) 420,854 (23.1%) 527,415 (28.9%) 73,612 (4%) 5,439 (0.3%) 2 (0-3) 95,473 (5.2%) 850,514 (46.6%) 24.9 (20.3-36)
Asthma
No asthma 8,324,393 2,488,381 (29.9%) 396,424 (4.8%) 1,701,714 (20.4%) 3,209,598 (38.6%) 487,942 (5.9%) 40,341 (0.5%) 2 (0-3) 623,238 (7.5%) 4,890,718 (58.8%) 21.2 (20-36)
With no oral steroid use 1,645,238 316,463 (19.2%) 75,740 (4.6%) 338,093 (20.5%) 727,489 (44.2%) 173,418 (10.5%) 14,028 (0.9%) 3 (2-3) 207,039 (12.6%) 1,124,333 (68.3%) 20.5 (19.8-26.2)
With oral steroid use 124,075 16,499 (13.3%) 5,418 (4.4%) 23,632 (19%) 50,596 (40.8%) 24,969 (20.1%) 2,961 (2.4%) 3 (2-3) 29,540 (23.8%) 90,258 (72.7%) 20.5 (14.5-24.9)
Diabetes
No diabetes 9,707,432 2,764,027 (28.5%) 463,449 (4.8%) 1,987,993 (20.5%) 3,844,778 (39.6%) 597,177 (6.2%) 50,001 (0.5%) 2 (0-3) 757,176 (7.8%) 5,833,128 (60.1%) 20.9 (20-36)
Controlled 294,301 38,213 (13%) 10,059 (3.4%) 56,217 (19.1%) 108,864 (37%) 74,844 (25.4%) 6,104 (2.1%) 3 (2-4) 85,925 (29.2%) 213,528 (72.6%) 20.5 (11-25.1)
Not controlled 10,381 1,183 (11.4%) 315 (3%) 1,652 (15.9%) 3,766 (36.3%) 3,269 (31.5%) 196 (1.9%) 3 (2-4) 3,675 (35.4%) 7,833 (75.5%) 20.5 (10.8-23.5)
Without recent Hb1ac measure 81,592 17,920 (22%) 3,759 (4.6%) 17,577 (21.5%) 30,282 (37.1%) 11,032 (13.5%) 1,015 (1.2%) 3 (1-3) 13,048 (16%) 50,820 (62.3%) 20.9 (19.6-27.8)
CKD or RRT
No CKD or RRT 10,070,599 2,818,004 (28%) 476,805 (4.7%) 2,059,883 (20.5%) 3,980,382 (39.5%) 681,156 (6.8%) 54,369 (0.5%) 2 (0-3) 851,858 (8.5%) 6,088,446 (60.5%) 20.9 (20-36)
CKD stage 3a 11,284 1,813 (16.1%) 392 (3.5%) 1,883 (16.7%) 4,249 (37.7%) 2,464 (21.8%) 490 (4.3%) 3 (2-4) 3,059 (27.1%) 7,980 (70.7%) 20.5 (11.3-25.8)
CKD stage 3b 2,604 364 (14%) 105 (4%) 434 (16.7%) 770 (29.6%) 749 (28.8%) 175 (6.7%) 3 (2-4) 952 (36.6%) 1,883 (72.3%) 20.3 (10.6-25.5)
CKD stage 4 1,435 210 (14.6%) 42 (2.9%) 231 (16.1%) 413 (28.8%) 427 (29.8%) 112 (7.8%) 3 (2-4) 539 (37.6%) 1,043 (72.7%) 20.3 (10.6-25.4)
CKD stage 5 455 77 (16.9%) 21 (4.6%) 84 (18.5%) 112 (24.6%) 133 (29.2%) 28 (6.2%) 3 (2-4) 161 (35.4%) 315 (69.2%) 20.3 (10.8-27.2)
RRT (dialysis) 3,171 497 (15.7%) 140 (4.4%) 476 (15%) 847 (26.7%) 693 (21.9%) 518 (16.3%) 3 (2-4) 1,176 (37.1%) 2,268 (71.5%) 20.3 (10.6-26.7)
RRT (transplant) 4,151 385 (9.3%) 84 (2%) 448 (10.8%) 910 (21.9%) 700 (16.9%) 1,631 (39.3%) 4 (3-5) 2,065 (49.7%) 3,374 (81.3%) 12.4 (4.4-21.9)
Organ transplant
No transplant 10,087,189 2,820,692 (28%) 477,428 (4.7%) 2,062,746 (20.4%) 3,986,255 (39.5%) 685,265 (6.8%) 54,803 (0.5%) 2 (0-3) 856,597 (8.5%) 6,100,045 (60.5%) 20.9 (20-36)
Kidney transplant 4,963 469 (9.4%) 105 (2.1%) 532 (10.7%) 1,099 (22.1%) 833 (16.8%) 1,925 (38.8%) 4 (3-5) 2,450 (49.4%) 4,018 (81%) 13 (4.6-22.1)
Other organ transplant 1,554 182 (11.7%) 49 (3.2%) 161 (10.4%) 336 (21.6%) 231 (14.9%) 595 (38.3%) 4 (2-5) 770 (49.5%) 1,246 (80.2%) 12.5 (4.1-21.6)
Hypertension
No 8,814,099 2,570,722 (29.2%) 431,333 (4.9%) 1,825,754 (20.7%) 3,415,069 (38.7%) 529,578 (6%) 41,650 (0.5%) 2 (0-3) 675,122 (7.7%) 5,245,534 (59.5%) 20.9 (20-36)
Yes 1,279,607 250,621 (19.6%) 46,249 (3.6%) 237,685 (18.6%) 572,621 (44.7%) 156,751 (12.2%) 15,673 (1.2%) 3 (2-3) 184,702 (14.4%) 859,782 (67.2%) 20.5 (19.8-26.5)
Chronic respiratory disease
No 10,029,859 2,810,563 (28%) 474,677 (4.7%) 2,051,707 (20.5%) 3,966,039 (39.5%) 672,210 (6.7%) 54,663 (0.5%) 2 (0-3) 842,198 (8.4%) 6,061,741 (60.4%) 20.9 (20-36)
Yes 63,840 10,780 (16.9%) 2,905 (4.6%) 11,739 (18.4%) 21,644 (33.9%) 14,112 (22.1%) 2,660 (4.2%) 3 (2-4) 17,626 (27.6%) 43,575 (68.3%) 20.5 (11-26.9)
Chronic cardiac disease
No 9,993,039 2,805,278 (28.1%) 473,592 (4.7%) 2,045,344 (20.5%) 3,953,600 (39.6%) 660,611 (6.6%) 54,614 (0.5%) 2 (0-3) 829,766 (8.3%) 6,035,071 (60.4%) 20.9 (20-36)
Yes 100,660 16,065 (16%) 3,990 (4%) 18,095 (18%) 34,090 (33.9%) 25,711 (25.5%) 2,709 (2.7%) 3 (2-4) 30,051 (29.9%) 70,245 (69.8%) 20.5 (11-26.7)
Cancer (non-haematological)
No 10,014,291 2,810,024 (28.1%) 475,195 (4.7%) 2,051,231 (20.5%) 3,952,263 (39.5%) 672,945 (6.7%) 52,633 (0.5%) 2 (0-3) 841,792 (8.4%) 6,046,446 (60.4%) 20.9 (20-36)
Yes 79,415 11,319 (14.3%) 2,387 (3%) 12,215 (15.4%) 35,427 (44.6%) 13,384 (16.9%) 4,690 (5.9%) 3 (2-3) 18,025 (22.7%) 58,870 (74.1%) 20.5 (15.6-24.4)
Haematological malignancy
No 10,074,498 2,818,543 (28%) 476,938 (4.7%) 2,060,457 (20.5%) 3,982,118 (39.5%) 682,857 (6.8%) 53,592 (0.5%) 2 (0-3) 852,943 (8.5%) 6,091,274 (60.5%) 20.9 (20-36)
Yes 19,208 2,800 (14.6%) 637 (3.3%) 2,989 (15.6%) 5,572 (29%) 3,472 (18.1%) 3,731 (19.4%) 3 (2-4) 6,874 (35.8%) 14,035 (73.1%) 20.3 (10.4-25.8)
Chronic liver disease
No 10,061,632 2,814,231 (28%) 475,874 (4.7%) 2,057,377 (20.4%) 3,978,457 (39.5%) 680,064 (6.8%) 55,636 (0.6%) 2 (0-3) 851,368 (8.5%) 6,085,282 (60.5%) 20.9 (20-36)
Yes 32,074 7,119 (22.2%) 1,708 (5.3%) 6,062 (18.9%) 9,233 (28.8%) 6,265 (19.5%) 1,687 (5.3%) 3 (1-3) 8,456 (26.4%) 20,034 (62.5%) 20.7 (11.3-28.1)
Stroke
No 10,066,679 2,816,674 (28%) 476,455 (4.7%) 2,058,728 (20.5%) 3,978,849 (39.5%) 679,504 (6.8%) 56,469 (0.6%) 2 (0-3) 851,739 (8.5%) 6,086,808 (60.5%) 20.9 (20-36)
Yes 27,027 4,676 (17.3%) 1,127 (4.2%) 4,711 (17.4%) 8,834 (32.7%) 6,825 (25.3%) 854 (3.2%) 3 (2-4) 8,078 (29.9%) 18,508 (68.5%) 20.5 (11-26.9)
Neurological disease
No 10,045,063 2,815,246 (28%) 476,042 (4.7%) 2,056,768 (20.5%) 3,974,229 (39.6%) 669,123 (6.7%) 53,655 (0.5%) 2 (0-3) 838,257 (8.3%) 6,068,013 (60.4%) 20.9 (20-36)
Yes 48,643 6,104 (12.5%) 1,540 (3.2%) 6,678 (13.7%) 13,461 (27.7%) 17,199 (35.4%) 3,661 (7.5%) 3 (2-4) 21,567 (44.3%) 37,296 (76.7%) 19.6 (10.6-22.8)
Asplenia
No 10,084,522 2,819,348 (28%) 477,148 (4.7%) 2,061,871 (20.4%) 3,985,282 (39.5%) 684,397 (6.8%) 56,469 (0.6%) 2 (0-3) 856,968 (8.5%) 6,099,387 (60.5%) 20.9 (20-36)
Yes 9,184 1,995 (21.7%) 434 (4.7%) 1,568 (17.1%) 2,401 (26.1%) 1,925 (21%) 854 (9.3%) 3 (1-4) 2,849 (31%) 5,929 (64.6%) 20.9 (10.8-28.3)
Rheumatoid arthritis, lupus, or psoriasis
No 9,765,833 2,761,871 (28.3%) 464,688 (4.8%) 1,999,774 (20.5%) 3,844,764 (39.4%) 648,837 (6.6%) 45,899 (0.5%) 2 (0-3) 809,095 (8.3%) 5,880,133 (60.2%) 20.9 (20-36)
Yes 327,866 59,479 (18.1%) 12,894 (3.9%) 63,672 (19.4%) 142,919 (43.6%) 37,485 (11.4%) 11,424 (3.5%) 3 (2-3) 50,729 (15.5%) 225,176 (68.7%) 20.5 (19.6-26)
Immunodeficiency
No 10,029,411 2,811,263 (28%) 475,314 (4.7%) 2,053,317 (20.5%) 3,969,084 (39.6%) 674,618 (6.7%) 45,815 (0.5%) 2 (0-3) 837,368 (8.3%) 6,058,745 (60.4%) 20.9 (20-36)
Yes 64,295 10,080 (15.7%) 2,268 (3.5%) 10,122 (15.7%) 18,606 (28.9%) 11,711 (18.2%) 11,508 (17.9%) 3 (2-4) 22,449 (34.9%) 46,571 (72.4%) 20.3 (10.4-26)
Learning disability
No 10,011,015 2,811,396 (28.1%) 474,663 (4.7%) 2,052,729 (20.5%) 3,967,740 (39.6%) 651,315 (6.5%) 53,172 (0.5%) 2 (0-3) 818,524 (8.2%) 6,041,182 (60.3%) 20.9 (20-36)
Yes 82,691 9,954 (12%) 2,919 (3.5%) 10,717 (13%) 19,943 (24.1%) 35,014 (42.3%) 4,151 (5%) 3 (2-4) 41,293 (49.9%) 64,134 (77.6%) 12.2 (10.4-21.9)
Severe mental illness
No 9,988,559 2,794,764 (28%) 471,205 (4.7%) 2,043,657 (20.5%) 3,958,472 (39.6%) 664,776 (6.7%) 55,678 (0.6%) 2 (0-3) 834,085 (8.4%) 6,042,666 (60.5%) 20.9 (20-36)
Yes 105,147 26,586 (25.3%) 6,377 (6.1%) 19,782 (18.8%) 29,211 (27.8%) 21,546 (20.5%) 1,645 (1.6%) 2 (0-3) 25,732 (24.5%) 62,643 (59.6%) 20.9 (13.8-36)


Abbreviations: CKD = chronic kidney disease; IMD = index of multiple deprivation; IQR = interquartile range; RRT = renal replacement therapy.


UK vaccine implementation in adults

An overview of COVID-19 vaccine implementation for UK adults is given below. Additional eligibility criteria can be found in COVID-19: the green book, chapter 14a.

  • Primary vaccination (2020-2021): All adults in the UK were offered a primary 2-dose series, with eligibility starting from December 2020 (over 80s, health and social care workers, and care home residents and staff) and extending to all adults over the early months of 2021.

  • Extended primary vaccination: Immunosuppressed individuals were offered a third primary dose from September 2021.

  • Autumn 2021 booster campaign: All adults were offered a booster dose, with eligibility starting from September 2021 (over 50s, health and social care workers, and care home residents, among others) and extending to all adults from November 2021.

  • Spring 2022 booster campaign: Over 75s, care home residents, and immunosuppressed individuals were offered an additional dose from March 2022.

  • Autumn 2022 booster campaign: Over 50s, care home residents and staff, immunosuppressed individuals, people aged 5-49 years in clinical risk groups or in close contact with immunosuppressed individuals, and carers aged 16-49 years were offered an additional dose from September 2022.

  • Spring 2023 booster campaign: Over 75s, care home residents, and immunosuppressed individuals were offered an additional dose from March 2023.

  • Autumn 2023 booster campaign: Over 65s, care home residents, people aged 6 months to 64 years in clinical risk groups, health and social care workers, people aged 12-64 years who are in close contact with immunosuppressed individuals, and carers aged 16-64 years are being offered an additional dose from September 2023.